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ABSTRACT
Prior studies linking breastfeeding duration and maternal gestational smoking,
respectively, to offspring eczema report contradictory findings. However, it is not known
whether maternal gestational smoking and breastfeeding duration can jointly influence eczema
and whether these exposures mediate their effect on eczema via DNA Methylation (DNA-M) of
CpG (cytosine-phosphate-guanine) sites.
With data from the Isle of Wight (IOW) birth cohort, UK, we first evaluated the
combined effect of maternal gestational smoking and breastfeeding duration on eczema at ages
1-to-2 (n=980), 4 (n=902), 10 (n=966), and 18 years (n=929) using Generalized estimating
equations (GEE). We found a protective effect of longer duration of breastfeeding (weeks) on
eczema if the mother smoked during gestation (objective (i)). The risk ratios (95% CI) for
eczema related to maternal gestational smoking for 3, 9, 15, 21 weeks of breastfeeding were 0.88
(0.66, 1.20), 0.74 (0.54, 1.01), 0.62 (0.41, 0.93), and 0.51 (0.3, 0.88), respectively.
Next, we investigated whether DNA-M at age 10 can mediate the effect of breastfeeding
duration on eczema at age 18 (n=276) using linear, log linear regression and structural equation
modelling. The CpGs cg03605610 (between NRC2 and LINC01276), cg04928096 (AXIN1),
cg26375057 (ZIC1) and cg26979504 (HHEX) were in the causal pathway between duration of
breastfeeding and eczema mediating its protective effect (indirect effect estimate: -0.008, pvalue: 0.022 (cg03605610); Estimate: -0.008, p-value: 0.049 (cg04928096); Estimate: -0.008, pvalue: 0.034 (cg26375057); Estimate: -0.007, p-value: 0.021 (cg26979504)).
Finally, we evaluated whether DNA-M at age 10 associated with combined effect of
gestational smoking and duration of breastfeeding can explain the risk of eczema using linear
and log linear regression. We found cg07208825 (ALMS1P), cg12954512 (Intergenic) and
iii

cg21601919 (FGF18) to be associated with duration of breastfeeding if the mother smoked
during gestation (Estimate: -0.006, p-value: 0.046 (cg07208825); Estimate: 0.021, p-value: 0.036
(cg12954512); estimate: 0.008, p-value: 0.016 (cg21601919). These CpGs were also associated
with eczema at age 18 (Risk-ratio: 14.23, p-value: 1.27E-07 (cg07208825); Risk-ratio: 0.62, pvalue: 3.90E-03 (cg12954512); Risk-ratio: 0.18, p-value: 1.56E-06 (cg21601919).
Future studies are required to corroborate these findings, and understand how the
breastmilk composition if the mother smoked during pregnancy influences these genes affecting
eczema pathogenesis.
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Chapter 1
INTRODUCTION
Eczema or atopic dermatitis is a chronic inflammatory skin disease associated with the
impaired epidermal barrier along with dryness and itching [1, 2]. It is an early onset disease
affecting over 20% of children in the developed countries, with rising prevalence in low income
countries [3]. Atopic dermatitis early in life can lead to development of allergic rhinitis and
asthma in adulthood [4] and is also associated with non-allergic comorbidities such as
rheumatoid arthritis and lung cancer [5, 6]. Apart from reduced quality of life, impaired
psychological and behavioral development, eczema also presents an economic burden on the
society [7]. In a recent National Health Interview Surveys in adults (ages 18-85 years) in the
United States, it has been found that those with eczema had $371 to $489 higher out-of-pocket
costs per person-year [7]. Likewise in Asia Pacific countries, the direct costs of atopic dermatitis
ranged from USD 199 in Thailand to USD 4,842 in Australia per patient per year [8] making it a
global economic and public health burden.
Eczema is can be explained by genetic factors and environmental factors [9]. The
deficiency of filaggrin [10] and the related “loss-of-function” genetic variants of the filaggrin
(FLG) gene have been found to be associated with heritable epidermal barrier function
impairment and eczema [9, 11, 12]. These mutations affect both priming and chronicity of
eczema and have been widely replicated [13]. Filaggrin (filament-aggregating protein)
represents an integral part of the epidermis which aids in combining the keratin filaments into
dense bundles at the granular layer–stratum corneum boundary. It is vital for the development of
the cornified envelope and to maintain the epidermal barrier function [11]. Filaggrin
haploinsufficiency, i.e. partial or complete loss of filaggrin protein, is associated with the
1

improper development epidermal barrier increasing water permeability of the skin allowing a
higher allergen penetration [14]. In a study by Ziyab et al, it has also been found that
combination of FLG variants and allergic sensitization leads to an increased risk of eczema in
subsequent years [15]. However, FLG loss of function only explains less than 10% of the disease
[16].
Apart from the genetics, several environmental exposures such as breast feeding and
smoking influence the pathogenesis of eczema [17, 18]. A review by Kramer states that
exclusive breastfeeding for at least 3 months is associated with a reduction in the risk of atopic
dermatitis at infancy [19]. In a study by Ito et al they demonstrated that longer breastfeeding is
associated with an increased risk of atopic dermatitis up to the age 42 months [20]. A
randomized trial comparing an intervention with prolonged and exclusive breastfeeding, reported
that there was a 54% lower risk of flexural eczema at age 16 years in the intervention group
compared to those who received usual care [21]. Chiu et al found breastfeeding for more than 6
months was associated with a significantly lower risk of developing eczema at ages 1 and 2 years
[22]. In a meta-analysis by Yang et al, they found a no strong evidence of exclusive
breastfeeding for at least 3 months to be protective effect against AD, even if the children had a
positive family history [23]. Thus, these findings indicate that the association of breastfeeding
and eczema is in dispute.
Maternal smoking during pregnancy also has been found to be associated with eczema
[24, 25]. Kim et al found that maternal smoking during pregnancy increased the risk of eczema
in a cross-sectional study [26]. Some studies have also reported a protective effect of maternal
smoking on eczema. A large study based in Denmark showed lower odds of atopic eczema at
ages 14-18 years if the mother smoked during late pregnancy [27]. Another large cohort study
2

found reduced odds of eczema at 5 years of age in children whose mothers smoked during
pregnancy [28]. Ek et al, reported that maternal smoking around birth is associated with a lower
odds of being diagnosed with eczema in a large study of UK biobank data in participants ranging
from ages 37 to 73 years [29].
The above studies show contradictory findings regarding the association of both smoking
during pregnancy and breastfeeding with eczema. If the mother smokes during pregnancy the
offspring is exposed to smoke in utero, and additionally components of smoke may be stored in
the breast fat tissues and passed on the child during breastfeeding [30, 31]. Interestingly, the
composition of tobacco smoke resembles that of coal tar, a traditional remedy for eczema [32]
which targets the skin barrier dysfunction. Similar to tobacco smoke, coal tar contains a lot of
high-molecular-weight hydrocarbons and polycyclic aromatic hydrocarbons (PAHs) [33]. To
improve the epidermal barrier function, coal tar induces a complex molecular mechanism by
activating the AhR/ARNT (aryl hydrocarbon receptor/ aryl Hydrocarbon Receptor Nuclear
Translocator) pathway [32]. Ligand activation of this pathway may activate EGFR signaling
leading to cell proliferation [34]. Downstream components of this signaling pathway also
regulate downstream the FLG (filaggrin), LOR (loricin), and K10 gene expression [35].
Regarding breastfeeding, it is known that if the mother smokes, nicotine, which has antiinflammatory effect [36] can be passed to the offspring via breastmilk [30]. Apart from nicotine,
cytokines such as IL-1α [37] and TNF-α[38], IL-1β and IL-8 [39] concentrations are different in
the breastmilk of mothers who smoked during pregnancy compared to non-smoking mothers
which may have an influence on inflammatory diseases like eczema.
It is not yet known how environmental exposures like breastfeeding and gestational
smoking mediate their effects. One possible mechanism by which breastfeeding may influence
3

eczema is by altering DNA methylation (DNA-M), an epigenetic mechanism that can change the
gene expression without mutation [40]. Findings suggest that the methylation of the 5th carbon of
cytosine nucleotides at cytosine-phosphate-guanine (CpG) sites in the DNA is affected by
environmental exposures [41] and that early life exposures can have a long-term effect on DNAM [42]. DNA-M is an epigenetic phenomenon involving addition of methyl groups to cytosine
bases in the cytosine-phosphate-guanine (CpG) sites on the DNA [43]. It can lead to a change in
gene expression without causing any mutation in the DNA [44]. Once differentially methylated,
the expression of the gene is altered [45] depending upon the position of the CpG on the gene,
thus translating the effect of environmental exposures into a biological mechanism. A lower
DNA-M of CpGs in the promoter region (regulatory region of the gene) may lead to a higher
gene expression; whereas that in the body region (region between the start and stop codon) is
known to modify transcriptional efficiency [44].
Interestingly, it has been found that in-utero smoke influence the DNA methylation
(DNA-M) of several of the above genes which are induced by coal tar including AHR, AHRR,
CYP1A1 [42, 46-49], even though the mode of intake of tobacco smoke is different from that of a
topical application of coal tar. The effect of maternal smoking during pregnancy has been
intensively investigated in the cord blood and CpGs belonging to the biological processes such as
nervous system development, phosphate-containing compound metabolism, and cell to cell
communication have been identified in a genome-wide Consortium Meta-analysis across 13
cohorts [50]. Although not many studies have explored the effect of breastfeeding duration on
DNA-M, in a recent meta-analysis five human studies were reported [51] linking breastfeeding
duration to methylation of the chromosome region 17q12, LEP (LEPTIN) gene, and also
influencing global methylation patterns [51].
4

To date the studies linking breastfeeding duration and gestational smoking, respectively
to eczema have produced conflicting results. Additionally, no prior studies have evaluated the
combined effect of both these early life exposures on eczema in the offspring. In the first aim of
this dissertation I aim to explore the effect of gestational smoking and breastfeeding duration
jointly on eczema. Although, present studies have identified CpGs in offspring associated
separately with gestational smoking and with breastfeeding duration, it not known yet whether
these critical early life exposures can be linked to methylation of CpGs that can explain the risk
of future eczema. Thus, in the second aim of this dissertation I will explore whether DNA-M can
explain the indirect effect of duration of breastfeeding on eczema. In contrast, in the third aim, I
will identify CpGs that are associated with the combined effect of gestational smoking and
duration of breastfeeding which in turn predict the risk of eczema.
Thus, the specific aims of this investigation are:
SA1: To assess whether the combined effect of gestational smoking and duration of
breastfeeding influence eczema throughout the first 18 years of life (1-18 years) Hypothesis 1:
Eczema development is influenced jointly by the early life exposures of gestational smoking and
duration of breastfeeding.
SA2: To explore the role of DNA-M as a mediator of the effect of duration of
breastfeeding on eczema. Hypothesis 2: DNA-M can explain the effect of duration of
breastfeeding on eczema via differential methylation of specific CpG sites.
SA3: To assess whether informative CpGs associated with a combined effect of
gestational smoking and duration of breastfeeding can in turn predict eczema. Hypothesis 3:
Gestational smoking and duration of breastfeeding can jointly influence DNA-M of specific
CpGs which can explain the risk of eczema.
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To this end we will analyze data from the Isle of Wight birth cohort, U.K (F0 and F1
generation) to assess the association of duration of breastfeeding, gestational smoking with
eczema. In SA1 I will investigate the joint effect of gestational smoking and duration of
breastfeeding on repeated measures of eczema at different time points in life (ages 1-2 years, 4,
10, and 18). For SA2 and SA3 in order to have a forward time order with the exposures
predicting DNA-M, and then DNA-M predicting eczema, I will analyze associations between
gestational smoking and duration of breastfeeding on DNA-M measured at age 10 years and
eczema at age 18 years.
This dissertation aims to investigate the effect of two environmental exposures (i.e.,
duration of breastfeeding and gestational smoking) on eczema in the offspring integrated with
epigenetic factors. These specific aims will help to bridge the knowledge gap regarding how the
interplay of breastfeeding duration and gestational smoking affects eczema and whether this
effect is mediated via epigenetic changes of specific genes.
The results of SA1 will demonstrate how gestational smoking and duration of
breastfeeding jointly predict eczema. In SA2, we will identify the CpG sites that are influenced
by breastfeeding duration and predict eczema. Thereafter, we will determine if these CpGs can
mediate the effect of breastfeeding on eczema. In contrast in SA3 we will identify the CpGs
which are influenced by the combined effect of gestational smoking and duration of
breastfeeding such that they predict the risk of eczema.
The results of SA1 will enhance our understanding regarding the combined effect of
critical early life exposures of gestational smoking and duration of breastfeeding on the
development of eczema. The genes of the CpGs identified in SA2 and SA3 will provide an
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insight regarding the molecular mechanism by which these exposures can alter the risk of
eczema contrasting the effect of duration of breastfeeding and the combined effect of both
duration of breastfeeding and gestational smoking on eczema. Overall, these results will help in
improved clinical management of eczema by modifying these early life exposures of gestational
smoking and duration of breastfeeding. Unlike genetic factors that are fixed at birth DNA-M is
influenced by environmental exposures and the identified CpGs can therefore serve as predictive
markers of eczema.

7

Chapter 2
BREASTFEEDING DURATION MODIFIES THE EFFECT OF SMOKING DURING
PREGNANCY ON ECZEMA FROM EARLY CHILDHOOD TILL ADOLESCENCE
Abstract
Background: Studies linking breastfeeding duration and gestational smoking, respectively, to
offspring eczema report contradictory findings.
Objective: To investigate the interaction of gestational smoking and breastfeeding duration on
the development of eczema from early childhood to adolescence.
Methods: Information regarding gestational smoking, breastfeeding duration, and eczema at age
1-to-2, 4, 10, and 18 years were obtained from the Isle of Wight (IOW) birth cohort, UK.
Generalized estimating equations (GEE) for repeated prevalence were used to assess this
interaction adjusting for confounders. Similar analyses were performed using persistent,
incidence, and remitting eczema determined repeatedly for three transition periods of age 1/2-4,
age 4-10, and age 10-18.
Results: Longer duration of breastfeeding (weeks) was associated with a lower risk of eczema if
the mother smoked during pregnancy. The risk ratios for eczema related to maternal smoking
and their 95% CI for 3, 9, 15, 21 weeks of breastfeeding were 0.88 (0.66, 1.20), 0.74 (0.54,
1.01), 0.62 (0.41, 0.93), and 0.51 (0.3, 0.88), respectively. Compared to no eczema in all three
transition periods, the risk of having persistent eczema was lowered if the mother smoked during
pregnancy with longer duration of breastfeeding.
Conclusions: Results suggest that a protective effect of breastfeeding duration against eczema if
the mother smoked during pregnancy. Future studies should investigate molecular pathways
influenced by both breastfeeding and cigarette smoking affecting eczema.
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Background
Eczema is a chronic relapsing inflammatory skin disease characterized by a disrupted
epidermal barrier [1, 2] with a lifetime prevalence ranging from 16-20% in the UK and US [26,
52], which is further increased in the developing countries [3]. Characteristically, an early onset
eczema often progresses to other non- or allergic diseases, a phenomenon that is called the atopic
march [53]. In addition to reducing quality of life [7, 52], eczema also poses an economic burden
on the society due to high cost of treatment [7, 8].
The “loss of function” mutation of the filaggrin (FLG) gene is a robustly replicated
genetic factor associated with eczema [12, 52]. However, the prevalence of filaggrin mutations
varies with populations [10], and these mutations do not fully explain the risk of eczema [54,
55]. This indicates a possible role of early life environmental exposures in the etiology of
eczema, such as maternal smoking during pregnancy and breastfeeding.
Enviromental exposures In utero occur during a critical time window of development
[56] and expoisure to maternal smoking in this period influences several long-term health
outcomes [57]. Kim et al found that exposure to maternal smoking during pregnancy increased
the risk of eczema in a cross-sectional study [26]. However, other studies have found no [58], or
a protective effect of maternal smoking during pregnancy for eczema in offspring [27, 28].
With respect to breastfeeding, several studies have explored its association with the
incidence of eczema in offspring and again have reported contradictory findings. A systematic
review by Kramer et al states that exclusive breastfeeding for ≥ 3 months is associated with a
reduction in the risk of eczema at infancy [19]. Elbert et al demonstrated that non-exclusive
breastfeeding is associated with a weak increase in the risk of eczema (adjusted odds ratio 1.11,
9

95%CI: 1.01, 1.23) [59]. Ito et al and Hong et al demonstrated that longer breastfeeding is
associated with an increased risk of atopic dermatitis in offspring [20, 60], whereas Lee et al
have reported null effects [61]. Turati et al described that early weaning is protective of eczema
[62]. Our group showed that in children with filaggrin loss of function mutation, a longer
duration of breastfeeding reduced the risk of eczema at age 1 or 2 years [63].
Although the above studies show contradictory findings regarding the association of both
smoking during pregnancy and breastfeeding with eczema, no study has yet investigated whether
combination of the two factors contribute towards the risk of eczema. We hypothesize that
maternal smoking during pregnancy and duration of breastfeeding jointly effect eczema. To this
end, we analyzed the interaction of duration of breastfeeding and maternal smoking during
pregnancy on eczema from infancy to late adolescence (ages 1 and 2, 4, 10 and 18 years) in boys
and girls using data from the Isle of Wight birth cohort.
Methods
Isle of Wight birth cohort
Isle of Wight birth cohort is a longitudinal cohort, established on the Isle of Wight, UK to
prospectively study natural history of allergic conditions. From January 1989 to February 1990
1,536 children were born on the Isle of Wight (IOW), among which, 1,456 mother-child pairs
were enrolled into the cohort study after exclusion of perinatal deaths, adoptions, and refusals.
Children were followed up at 1, 2, 4, 10 and 18 years of age. This study represents a dynamic
cohort since some children did not participate at some assessments but rejoined in the next.
The research ethics committee on the IOW (NRES Committee South Central - Hampshire
B, U.K.), and in Memphis (University of Memphis Institutional Review Board, FWA00006815)
10

approved the study and informed written parental consent was obtained for all participants at
recruitment and subsequently at each follow-up. The IOW birth cohort has been described in
detail elsewhere [64-66].
Data collection
Information regarding eczema symptoms was acquired though detailed interviews and
examinations at the follow-ups at 1, 2, 4, 10, and 18 years. A postal or telephone questionnaire
was sent if a visit was not possible [67].
Eczema was defined according to the Hanifin and Rajka criteria [68] as chronic or
chronically relapsing, itchy dermatitis lasting more than 6 weeks with characteristic morphology
and distribution [69]. Since the 1st year and 2nd year follow up was conducted in a small time
window, we combined them for analytical purposes.
Smoking during pregnancy of the mothers was ascertained at birth. Postnatal smoking
was ascertained by asking at the follow-ups at 1and 2 years whether there is any smoking inside
the house.
Regarding breastfeeding, the mother was asked at the 1- and 2-year follow-up whether
the child was breastfed and the total duration of breastfeeding (in weeks). In addition, age of
starting formula feeding (in weeks) was also ascertained. Duration of exclusive breastfeeding
(weeks) was determined by comparing the total duration of breastfeeding with the age of
initiating formula feeding or introduction of solid foods.
Socioeconomic status, maternal and paternal eczema, FLG loss of function genetic
variants, and gender were included as confounders since they potentially associate with maternal
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smoking, breastfeeding duration, and eczema. Parental occupation was reported at birth, number
of children in the index child’s bedroom was collected at age 4 years, and family income was
ascertained at age 10 years. These three variables were clustered to produce a family social status
variable used in our analyses [70]. Gender, and maternal and paternal eczema were determined at
birth.
Genotyping
DNA samples were extracted from 1,150 cohort participants from blood or saliva and
assessed using GoldenGate Genotyping Assays (Illumina, Inc, SanDiego, CA) on the
beadXpressVeracode platform (Illumina, Inc, SanDiego, CA) per Illumina’s protocol. Data were
analyzed using the genotyping module of the GenomeStudio Software package (Illumina, Inc,
SanDiego, CA). Individuals carrying the minor allele for at least one of the FLG variants R501X,
2282del4, or S3247X were classified as having filaggrin haploinsufficiency [15].
Statistical analysis
Assessing the interaction of maternal gestational smoking and duration of exclusive
breastfeeding on eczema prevalence
Eczema status repeatedly measured at age 1-or-2 (year 1 and 2 combined), 4, 10, and 18
years was analyzed using the generalized estimating equation (GEE) approach [71]. Since the
prevalence of eczema is higher than 10% at each time point, risk ratios [72] were estimated using
the log link function. Loss of function filaggrin genetic polymorphisms, age started formula
feeding, gender, socioeconomic status of offspring at age 10, maternal and paternal eczema
status, and gestational age were included in the model as potential confounders. We started with
a model containing all main effects and the interaction of maternal smoking during pregnancy
12

and duration of exclusive breastfeeding. After evaluation of whether the interaction term was
significant, we assessed confounding on the joint effect of duration of exclusive breastfeeding
and maternal smoking during pregnancy i.e., RR= exp (β1×maternal smoking during pregnancy +
β2×duration of exclusive breastfeeding +β3× (maternal smoking during pregnancy × duration of
exclusive breastfeeding)).
Additionally, to further evaluate whether the effect of breastfeeding duration differs if the
mother smokes during pregnancy vs. not, we also performed a stratified analysis by maternal
smoking status during pregnancy using model with repeated measures of eczema.
In addition to maternal smoking during pregnancy we compared also investigated the
effect of post-natal exposure to smoke within 1-or-2 years (year in which the mother breastfed)
had an effect on eczema. To this end, we created a variable by combining smoking during
pregnancy and postnatal smoking and assessed its interaction with duration of exclusive
breastfeeding on eczema.
The effect of maternal smoking during pregnancy may linger on to the first years of life
when the child is exposed to breastmilk. Hence, it is difficult to assess the independent effects of
both exposure for eczema. To prepare independent variables, we calculated the residual duration
of exclusive breastfeeding not explained by smoking during pregnancy by using linear regression
and repeated the analysis with the residuals. We assessed the interaction effect of the residual
breastfeeding duration and maternal smoking during pregnancy on eczema using log linear
models.
A p-value ≤ 0.05 was used to indicate statistical significance. Statistical analyses were
performed using the SAS statistical package (version 9.4; SAS Institute, Cary, NC, USA).
13

Assessing the interaction of maternal gestational smoking and duration of exclusive
breastfeeding on patterns of persistent, remitting, or incident eczema
The logistic regression with repeated measurements of eczema considers the prevalence
of eczema at the time points of age 1-or-2, 4, 10, and 18, but does not provide insights regarding
the consistency of the disease, i.e., whether it was persistent, remitting, or incident eczema. To
heuristically identify such patterns of eczema , we applied a configural frequency analysis (CFA)
using a FORTRAN CFA program by von Eye [73]. The CFA analysis identifies the profile of the
eczema status at age 1-or-2, 4, 10, and 18 (yes/no). It generates types (patterns that occur
significantly more often than by chance) and antitypes (patterns that occur significantly less
often than by chance) of the variable from the data. We performed CFA first by excluding any
missing eczema information at all the time points (n=1006) (supplementary table A3) using first
order CFA with normal approximation of the binomial test, adjusted for multiple testing using
Bonferroni correction.
Next, for the transition of age 1-or-2 to 4 years we created a variable that had the value of
‘1’ if eczema present at both time points, and ‘0’ if eczema is not present at both time points,
thus comparing persistent vs. never eczema. We created similar variables for the other two
transitions from age 4 to 10 years, and 10 to 18 years, respectively. Using the repeated
transitions, we evaluated the interaction of maternal smoking during pregnancy with exclusive
breastfeeding duration using log linear regression with GEE approach. Similarly, we assessed the
interaction with repeated measures of remitting vs. never, and incident vs. never at all three
transitions.
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Results
There was no significant difference in the prevalence of eczema, duration of exclusive
breastfeeding, maternal smoking during pregnancy, FLG loss of function variants, gender,
socioeconomic status, and maternal and paternal eczema status between the whole cohort
(n=1,150), and the sample analyzed at ages 1-2, 4, 10, and 18 (Table 1 and Table 2).
To explore the interplay of maternal smoking during pregnancy and duration of exclusive
breastfeeding we plotted the data against the proportion of eczema separately at four time points.
We categorized the duration of exclusive breastfeeding into none, 1-15 weeks and more than 15
weeks (Figure 1). The plots revealed that the proportion of eczema varies between those whose
mothers smoked during pregnancy compared to those with non-smoking mothers in different
categories of breastfeeding.
We then analyzed the interaction effect between maternal smoking during pregnancy and
duration of exclusive breastfeeding, on repeated measures of eczema at age 1-or-2, 4, 10, and 18
years using generalized estimating equations (GEE) (Table 3). The model was adjusted for
socioeconomic status, maternal and paternal eczema, FLG loss of function genetic variants, and
gender. The results indicate that the interaction of exclusive breastfeeding and maternal smoking
during pregnancy is significantly associated with eczema in offspring (p-value: 0.04).
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Table 1. Comparison of prevalence of eczema at ages 1-2 years, 4 years, 10 years, and 18
years between whole cohort and sample analyzed@. In addition, number of participants
analyzed with incident, persistent, remitting eczema in the three transitions* of age 1-or-2 to
4, age 4 to 10, and age 10 to 18 are also presented.
Total cohort
Sample analyzed
pN (%)
n (%)
value
Age 1 or 2 years
N=1150
n=980
Yes
162 (14.09)
153 (15.61)
0.73
Prevalence
No
914 (79.48)
827 (84.39)
Missing
74 (6.43)
Age 4
N=1150
n=902
Yes
119 (10.35)
105 (11.64)
0.91
Prevalence
No
889 (77.30)
797 (88.36)
Missing
142 (12.35)
N=957#
n=902#
Incidence
46/ 957 (4.8)
43/ 902 (4.8)
0.99
Transition
Persistence
66/ 957 (6.9)
62/ 902 (6.9)
from age 1-2
Remission
88/957 (9.2)
86/ 902 (9.5)
to 4 years
None
757/ 957 (79.1)
711/ 902 (78.8)
Age 10
N=1150
n=966
Yes
164 (14.26)
142 (14.70)
0.98
Prevalence
No
954 (82.96)
824 (85.30)
Missing
32 (2.78)
N=991#
n=888#
Incidence
80/ 991 (8.1)
69/ 888 (7.8)
0.99
Transition
Persistence
64/ 991 (6.5)
58/ 888 (6.5)
from age 4
Remission
50/ 991 (5.1)
44/ 888 (5.0)
to 10 years
None
797/ 991 (80.4)
717/ 888 (80.7)
Age 18
N=1150
n=929
Yes
132 (11.48)
110 (11.84)
0.83
Prevalence
No
954 (82.96)
819 (88.16)
Missing
64 (5.57)
N=1054#
n=915#
Transition
Incidence
63/1054 (6.0)
54/915 (5.9)
0.99
from age 10
Persistence
63/1054 (6.0)
52/915 (5.7)
to 18 years
Remission
87/1054 (8.2)
78/ 915 (8.5)
None
841/1054 (79.8)
731/ 915 (79.9)
@
Sample analyzed is sample with no missing for any of the covariates in the model.
*Eczema in transition periods are defined as incident (present in the second time point but not
in the first), persistent (present at both time points), remitting (present at first time point but
not in the second).
#
Only participants with no missing eczema information at both time points are considered,
e.g., 991 out of 1150 had eczema information at both ages 4 and 10 years. Similarly, in the
analyzed sample out of 966 only 888 had eczema information at both ages 4 and 10 years.
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Table 2. Distribution of potential risk factors and confounders in the birth cohort and the analytical sample.
Total
Sample at
Sample at
Sample at
Sample at
cohort
Age 1-2
Age 4
Age 10
Age 18
(N=1150)
(n=980)
p(n=902)
p(n=966)
p(n=924)
Covariates
(n%)
(n%)
value
(n%)
value
(n%)
value
(n%)
Maternal
0.44
0.12
0.38
smoking
Yes
266
214
184
209
192
No
879
766
718
757
737
Missing
5
FLG loss of
0.91
0.84
0.88
function variants
Yes
118
102
95
101
95
No
1032
878
807
865
834
Missing
Maternal eczema
0.90
0.76
0.94
status
Yes
143
121
109
120
118
No
998
859
793
846
811
Missing
9
Paternal eczema
0.99
0.8
0.93
status
Yes
80
69
61
69
67
No
1055
911
841
897
862
Missing
15
Socio economic
0.90
0.17
0.70
cluster
Low
161
139
108
133
125
Mid
851
755
711
747
721
High
98
86
83
86
83
0.61
0.87
0.64
Gender
Male
569
474
443
468
440
Female
581
506
459
498
489
17

pvalue
0.16

0.98

0.91

0.89

0.59

0.34

Table 2 (continued). Distribution of potential risk factors and confounders in the birth cohort and the analytical sample.

Covariates
Exclusive
breastfeeding
duration (weeks)
Weeks of
gestation

Total
cohort
(N=1150)

Sample at
Age 1-2
(n=980)

Sample at
Sample at
pat Age 4
pat Age 10
value
(n=902)
value
(n=966)
Median (minimum, maximum)

6 (0, 80)

6 (0, 80)

0.76

6 (0, 80)

0.46

40 (28, 45)

40 (30,45)

0.59

40 (30, 45)

0.35
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pvalue

Sample at
Age 18
(n=924)

pvalue

6 (0, 80)

0.67

6 (0, 76)

0.77

40 (30, 45)

0.63

40 (30, 44)

0.56

Figure 1. Comparison of the prevalence of eczema over increasing duration of breastfeeding
(categorized in 15 week interval) if with or without maternal smoking during pregnancy at ages 1-2 years,
4 years, 10 years and 18 years.
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Table 3. Association of maternal smoking during pregnancy and duration of exclusive breastfeeding with eczema at ages 1or-2, 4, 10, and 18 adjusted for covariates. Transition 1,2 and 3 pertain to the transition from age 1-2 years to 4 years; 4 years
to 10 years; and 10 years to 18 years
Outcome: Eczema prevalence at all the Outcome: Eczema persistence at all three
time points (n=3777)
transitions (n=2331)
Risk ratio
pRisk ratio
pParameter
Levels
(95% CI)
value
(95% CI)
value
Maternal smoking during pregnancy
0.97 (0.70, 1.36)
0.87
0.79 (0.45, 1.40)
0.42
Duration of exclusive breastfeeding
1.00 (0.99, 1.01)
0.87
0.99 (0.98, 1.01)
0.75
Maternal smoking during pregnancy ×
0 weeks
0.97 (0.70,1.36)
0.87
0.8 (0.45, 1.42)
0.45
Duration of exclusive breastfeeding#*
3 weeks
0.88 (0.66, 1.20)
0.44
0.7 (0.4, 1.22)
0.19
9 weeks
0.74 (0.54, 1.01)
0.06
0.54 (0.30, 0.95)
0.03
15 weeks 0.62 (0.41, 0.93)
0.02
0.41 (0.21, 0.82)
0.01
21 weeks 0.51 (0.30, 0.88) 0.016
0.31 (0.13, 0.74)
0.009
FLG loss of function variants
1.57 (1.16, 2.12) 0.0034
1.91 (1.19, 3.06)
0.007
Time
Year 1/ 2
Ref.
Ref. Transition 1
Ref.
Ref.
Year 4
0.74 (0.62, 0.89) 0.0012 Transition 2 1.02 (0.97, 1.08)
0.40
Year 10 0.95 ( 0.80, 1.12)
0.54 Transition 3 0.89 (0.74, 1.07)
0.21
Year 18
0.76 (0.63, 0.93)
0.08
Weeks of gestation
1.1 (1.0, 1.21)
0.034
1.1 (0.93, 1.31)
0.24
Maternal eczema status
1.31 (0.98, 1.76)
0.06
1.26 (0.75, 2.09)
0.38
Paternal eczema status
1.74 (1.26, 2.41) 0.0008
2.09 (1.26, 3.46)
0.004
Gender (Female is the reference)
Male
0.94 (0.75, 1.17)
0.57
0.97 (0.67, 1.41)
0.89
Socio economic status
Mid
0.98 (0.67,1.42)
0.90
1.02 (0.56, 1.90)
0.93
(High socioeconomic status)
Low
0.92 (0.58, 1.45)
0.70
0.81 (0.36, 1.86)
0.63
# Overall significance is 0.04 when the outcome is eczema prevalence at ages 1-or-2, 4, 10, and 18 years.
*Overall significance is 0.03 when the outcome is persistent eczema for all transitions from age 1-or-2 to 4 years; age 4 to 10 years; age 10 to 18 years
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Maternal smoking was not associated with eczema if the mothers did not breastfeed (RR:
0.97 (95%CI: 0.70, 1.36)). However, the risk of eczema if the mother smoked was lower as
duration of breast feeding increases showing a dose response relationship. Compared to no
maternal smoking, if the mother smoked the risk of eczema decreases over duration of exclusive
breastfeeding. The risk ratio at 3, 9, 15, 21 weeks were 0.88 (95%CI: 0.66, 1.20), 0.74 (95%CI:
0.54, 1.01), 0.62 (95%CI: 0.41, 0.93), and 0.51 (95%CI: 0.3, 0.88), respectively (Table 3, Figure
2). Among the other covariates, FLG loss of function variants, weeks of gestation, maternal and
paternal history of eczema, were significantly associated with risk of eczema.

Figure 2. Risk of eczema in offspring with increasing duration of breastfeeding if the mothers
smoked during pregnancy compared to non-smoking during pregnancy for repeated
measurements of the prevalence eczema at ages 1-2 years, 4 years, 10 years and 18 years
(n=3777)
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To further inspect whether duration of exclusive breastfeeding is protective of eczema if
the mother smoked during pregnancy, we stratified the analyses by maternal smoking
(Supplementary table A1). In the strata where the mothers did not smoke, there was no
association between duration of exclusive breastfeeding and eczema (overall RR in non-smokers:
1.00, 95%CI: 0.99, 1.01). However, in the strata with maternal smoking, the risk ratio of eczema
was lower in the offspring with longer duration of breastfeeding compared to no breastfeeding.
Risk ratios for exclusive breastfeeding at 3, 9, 15, 21 weeks are 0.91 (95%CI: 0.84, 0.99), 0.76
(95%CI: 0.58, 0.98), 0.63 (95%CI: 0.41, 0.93), and 0.52 (95%CI: 0.28, 0.95), respectively
(Supplementary table A1).
The effect of maternal smoking during pregnancy on eczema may extend to the initial
years of life, making it difficult to differentiate between the effects of breastfeeding and maternal
smoking during pregnancy. Hence, both variables are not independent. In an additional step, we
produced independent variables by calculating the residual exclusive breastfeeding duration that
is not explained by maternal smoking status during pregnancy using linear regression. These
residuals were proportional to duration of exclusive breastfeeding. Analyses using GEE method
showed a significant interaction between residuals of exclusive breastfeeding duration
(Supplementary table A2, overall RR: 0.98, 95% CI: 0.96, 0.997, p-value: 0.02). The risk ratios
show a similar decreasing trend of the risk ratios if the mother smoked during pregnancy and
duration of exclusive breastfeeding 3, 9, 15, 21 weeks 0.74 (95%CI: 0.54, 1.00), 0.61 (95%CI:
0.40, 0.93), 0.51 (95%CI: 0.29, 0.89), and 0.42 (95%CI: 0.21, 0.86), respectively
(Supplementary table A2).
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Identifying patterns of eczema using configurational frequency analysis (CFA)
The CFA analysis without missing data of four eczema variables (Yes/No) at ages 1-or-2,
4, 10, and 18 years, respectively yielded five types i.e., patterns of eczema that occur
significantly more often than by chance (Supplementary table A3). One of the five type
configurations predicted no eczema, and the other four predicted having eczema at three or all
four times, indicating that eczema was present statistically significantly more frequent across
the time points (persistent eczema). Hence, we compare the dynamic pattern or singular
occurrence or multiple occurrence of the disease.
The results of repeated measurement analyses with GEE method in logistic regression
revealed that the risk of persistent eczema is lower compared to no eczema with longer duration
of exclusive breastfeeding if the mother smokes during pregnancy (Table 3). The risk of
persistent eczema if the mother smokes for duration of exclusive breastfeeding at 0, 3, 9, 15, 21
weeks were 0.8 (95%CI: 0.45, 1.42), 0.7 (95%CI: 0.4, 1.22), 0.54 (95%CI: 0.30, 0.95), 0.41
(95%CI: 0.21, 0.83), and 0.31 (95%CI: 0.13, 0.74), respectively. The interaction was not
significantly associated with remission vs. none, or incident vs. none eczema.
Discussion
In this longitudinal and prospective birth cohort study we demonstrated that if the mother
smokes during pregnancy, a longer duration of exclusive breastfeeding is protective of eczema in
offspring measured repeatedly at 1-2, 4, 10, and 18 years (p–value: 0.04). The risk ratios were
0.88 (95%CI: 0.66, 1.20), 0.74 (95%CI: 0.54, 1.01), 0.62 (95%CI: 0.41, 0.93), and 0.51 (95%CI:
0.3, 0.88), at 3, 9, 15, and 21 weeks of duration of exclusive breastfeeding, respectively. To
further examine this, we stratified the analysis by maternal smoking, and found that longer
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breastfeeding duration was protective of eczema only in the strata where mothers smoked during
pregnancy. The risk ratios for exclusive breastfeeding at 3, 9, 15, 21 weeks were 0.91 (95%CI:
0.84, 0.99), 0.76 (95%CI: 0.58, 0.98), 0.63 (95%CI: 0.41, 0.97), and 0.52 (95%CI: 0.28, 0.95),
respectively. In addition, for the three transitions of age 1-2 to 4 years, age 4 to 10 years, and age
10 to 18 years, the interaction of maternal smoking during pregnancy and exclusive
breastfeeding duration was significantly associated with persistent eczema compared to never
eczema.
In the past, several studies have separately assessed the effect of maternal smoking during
pregnancy, and duration of breastfeeding, respectively on eczema and reported contradictory
results [58, 74, 75]. Our findings indicated that combinations of these two factors influence early
onset persistent eczema in the offspring and provide a potential explanation for the previous
conflicting reports.
There was no significant difference in the study characteristics of the whole cohort and
the study participants at ages 1-2, 4, 10, and 18 years indicating that a selection bias is unlikely.
The diagnosis of eczema was made using the questionnaire based on Hanifin and Rajka’s criteria
[76]. The chances of misclassification are low since the participants developed rashes in typical
locations (anticubital or popliteal fossae, ankles, face or neck) validating the eczema definition
[76]. All questionnaires focused on eczema in the preceding 12 months to minimize the potential
for recall bias that might occur if participants were asked to recall the entire period between
assessments.
One of the limitations of this study could be that the maternal smoking status is selfreported. However, we have assessed the DNA methylation of a CpG (cytosine-phosphate-
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guanine) site cg05575921 of the AHRR (Aryl-Hydrocarbon Receptor Repressor) gene, a wellestablished epigenetic biomarker of smoking. The offspring whose mothers smoked during
pregnancy had significantly lower cord blood methylation of this CpG site at birth (estimate: 0.43 and p-value: 0.009), which is in agreement with the prior studies of prenatal smoke
exposure and supports the validity of the smoking information [48]. Breastfeeding duration was
determined retrospectively from the mothers at ages 1 year and 2 year follow up. It is unlikely to
be affected by recall, since it has been shown that maternal recall within <=3 years provides a
valid and reliable estimate of breastfeeding history [77].
It is known that the effect of maternal smoking during pregnancy on the offspring may
extend to the first year of life or even longer [57]. Given that exposure to breastfeeding also takes
place during the first year of life, it is important to distinguish these two effects on eczema. To
take this into account in the analysis, we regressed duration of exclusive breastfeeding on
maternal smoking during pregnancy and calculated the residual duration of exclusive
breastfeeding. The interaction of residual exclusive breastfeeding duration and maternal smoking
during pregnancy showed a similar significant protective effect on eczema with longer duration
of breastfeeding.
Apart from assessing the effect of maternal smoking during pregnancy, we performed an
additional analysis combining the variables of maternal smoking during pregnancy and postnatal
smoking within 1-or-2 years (year in which the mother breastfed) and checked its interaction o
with duration of exclusive breastfeeding on eczema. We found a similar protective effect of
smoking in pregnancy and/or the first year of life on eczema if the mother breastfeeds
exclusively for a longer duration (Supplementary table A4) compared to non-smoking mothers.
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Regarding biological mechanism, existing studies suggest that breast milk contains
proteins [78] and fatty acids [79] that may stimulate or suppress the immune response affecting
eczema. Other studies propose in utero smoke exposure changes the T lymphocyte system
linking to eczema [28]. None of the studies have yet connected both maternal smoking during
pregnancy and gestational smoking and linked these to eczema. However, we found no
association of maternal smoking with offspring eczema if the mother did not breastfeed (i.e., 0
weeks in Table 3) and the protective effect was more pronounced at women with longer duration
of breastfeeding. This indicates that it is not in utero smoke exposure alone that produces a
protective effect, and that a significant protective effect is only found if the smoking mother had
breastfed for ≥ 9 weeks. Interestingly, tobacco smoke contains compounds such as polycyclic
aromatic hydrocarbons (PAHs) similar to coal tar, a topical remedy of eczema [33]. Enzymes of
cytochrome P450 family involving the AHR and ARNT genes detoxify these high molecular
weight compounds, in turn, PAHs may induce filaggrin production alleviating eczema [80, 81].
If the mother smokes during pregnancy, tobacco components being lipophilic in nature, are
stored in maternal breast fat tissue [82] and may be passed to the infant via breast milk [83].
Thus, longer breastfeeding duration offspring exposed to the coal tar like compounds present in
cigarette smoke in-utero may experience a different risk of eczema if the mother breastfed the
child.
Our findings suggest that interaction of maternal smoking during pregnancy and
breastfeeding duration is associated with non-remitting persistent eczema at age 1-or-2, 4, 10,
and 18 years suggesting a long term effect protective effect of these early life exposures towards
early onset and chronic eczema. It is possible that components of cigarette smoke passed through
breastmilk may influence the AHRR/ARNT system triggering filaggrin and reducing eczema.
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Thus, our results suggest that mothers who do not quit smoking during pregnancy should
continue to breastfeed the offspring for the longest period possible, since a longer duration of
exclusive breastfeeding may be protective of eczema in these children. Future studies should
explore the underlying biological mechanisms by examining the genetic, molecular, and
epigenetic pathways influenced by breastfeeding and cigarette smoking in relation to eczema.
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Chapter 3
DNA METHYLATION MEDIATES THE LONG TERM EFFECT OF BREASTFEEDING
DURATION ON ECZEMA AT AGE 18

Abstract
Rationale: Studies suggest that longer breastfeeding duration may be protective of eczema. We
hypothesize that this protective effect is mediated by DNA methylation (DNA-M).
Methods: Peripheral blood sample was collected at age 10 years (n=276). Breastfeeding duration
information was obtained at age 1-2 years and eczema information ascertained at age 18 year
follow up. DNA-M of CpG (cytosine-phosphate-guanine) sites was assessed using the Illumina
HumanMethylation450K and 850K BeadChips. In hierarchical screening steps, we identified
CpGs at age 10 years associated with breastfeeding duration at α≤0.05 (linear regression) and
eczema at age 18 years (log linear regression) followed by multiple testing adjustment (FDR pvalue<=0.05) and confounding assessment. The significant CpGs were then tested in structural
equation analyses. To influence by eczema at age 10 on DNA-M at age 10 years we included
only the children who were eczema-free at age 10 years (n=276).
Results: Longer breastfeeding duration was associated with higher DNA-M at age 10 years of
cg03605610 (between NRC2 and LINC01276), cg04928096 (AXIN1), cg26375057 (ZIC1) and
cg26979504 (HHEX). Higher DNA-M at age 10 years of these CpGs was associated with lower
risk of eczema at age 18 years. Structural equation modelling revealed significant indirect effects
indicating that methylation of these CpGs at age 10 years are in the causal pathway between
duration of breastfeeding and eczema at age 18 (Indirect effects: Estimate: -0.008, p-value: 0.022
for cg03605610; Estimate: -0.008, p-value: 0.049 for cg04928096; Estimate: -0.008, p-value:
0.034 for cg26375057; Estimate: -0.007, p-value: 0.021 for cg26979504).
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Conclusion: DNA-M of specific genes may mediate the protective effect of longer breastfeeding
duration on eczema.
Background

Eczema, an inflammatory disease accompanied with epidermal barrier dysfunction, is
increasing worldwide in children and adolescents [3, 84]. It causes significant morbidity such as
dryness, scaling and itching of the skin in early life and may progress to other allergic diseases
later in life, a phenomenon named as ‘allergic march’ [4]. The strongest genetic factor associated
with eczema that has been identified to date is loss of function mutations of the filaggrin (FLG)
gene [12] found in varying proportions in ethnicities and regions (17% to 42% in Caucasian
populations and 20% to 30% in Asian populations) [85-87] However, presence of FLG LOF
mutations explain less than 10% of all eczema cases [16].

In addition to genetic factors, several environmental factors are associated with the risk of
eczema, one of which is breastfeeding. In a recently conducted meta-analysis, Lodge et al found
that exclusive breastfeeding compared to other feeding types was associated with a reduced risk
of eczema below 2 years of age [88]. An ISAAC phase three study reported a protective effect of
ever breastfeeding with severe eczema (OR 0.79, 95% CI 0.66–0.95) in children aged 6-7 years
[89]. Focusing on delayed long-term effects of breastfeeding on eczema, Saarinen et al found
longer duration of breastfeeding to be protective against atopic eczema in a prospective follow
up study from childhood to adolescence [90]. Elbert et al showed that shorter duration of
breastfeeding increased the risk of eczema [59]. Others have reported null association [61, 91]
and even an opposite effect, showing early weaning to be protective for eczema [62]. Our group

29

demonstrated that among children with the FLG loss of function variants, eczema risk at age 1 or
2 years reduced with longer breastfeeding duration [63].

Although several studies have found breastfeeding to be protective for eczema, it is not
yet known how breastfeeding may mediate a protective effect against eczema. One possible
mechanism by which breastfeeding may influence eczema is by altering DNA methylation
(DNA-M), an epigenetic mechanism that can change the gene expression without mutation [40].
Findings suggest that the methylation of the 5′ carbon of cytosine nucleotides at cytosinephosphate-guanine (CpG) sites in the DNA is affected by environmental exposures [41] and that
early life exposures can have a long-term effect on DNA-M [42]. To date there have been very
few studies exploring associations between breastfeeding and DNA-M. A recent meta-analysis
reported five human studies [51] showing a link between breastfeeding duration with global
methylation pattern [92] and with LEP promoter methylation [93]. The other studies in the metaanalysis reported that breastfeeding duration modifies effects of genetic variants on the
methylation of the chromosome region 17q12 [94]; and that never breastfeeding was found to be
associated with higher odds of methylation (Yes/ No) of the CDKN2A promoter [95]. However,
none of the studies have yet investigated whether the DNA-M may mediate the effect of
breastfeeding on the skin to protect against eczema.

To this end, we analyzed data from the two-generational Isle of Wight birth cohort, U.K.
to identify methylation sites at age 10 years in peripheral blood that may mediate the protective
effect of duration of breastfeeding on eczema at age 18 years in the F1 generation. We used a
hierarchical screening approach to identify informative CpGs and applied structural equation
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analyses to assess the indirect effect of duration of breastfeeding on eczema via the selected
CpGs.

Methods
Study population
In 1989 a population based birth cohort (n=1536) was established on the Isle of Wight,
UK, to prospectively study natural history of allergic conditions (F1 generation). 1,536 F1children were born on the Isle of Wight (IOW), from January 1989 to February 1990, among
which, 1,456 F0-mother-F1-child pairs were enrolled into the cohort study after excluding
adoptions, perinatal deaths, and refusals. Follow up of these F1 children was conducted at 1, 2, 4,
10 and 18 years of age [96]. The children of these F1 participants were also enrolled in the study
(F2-offspring). Cord blood was collected from the F2-offspring for DNA methylation and gene
expression measurements.

The Institutional Review Board of the University of Memphis and the local research
ethics committee (South Central - Hampshire B Research Ethics Committee) approved the study.
for All participants provided informed written parental or child’s consent (at age 18 years) at
recruitment and each follow-up. The IOW birth cohort has been described in detail elsewhere
[64-66]. In this study we focus on the DNA-M of peripheral blood samples collected from a
sample of boys and girls from Guthrie cards (collected within a week after birth), and at 10 years
of age (F1 generation), and on DNA-M from cord blood samples collected at delivery of F2offspring (F2 generation).
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Phenotypes
At age 18 years follow up eczema symptom information was acquired though detailed
interviews and examinations. Eczema was defined as per the the Hanifin and Rajka criteria [68]
as itchy dermatitis lasting more than 6 weeks which is chronic or relapsing with characteristic
distribution and morphology [69].Mother was asked at 1- and 2-year follow-ups of the F1
generation, if the child was breastfed and the total duration of breastfeeding in weeks. Maternal
smoking was determined at birth. A postal or telephone questionnaire was completed if a visit
was not possible [67]. In F2 generation duration of breastfeeding and eczema was assessed in F2
children at 3, 6, and 12 months of age, maternal smoking was determined at birth.

The confounding variables considered in the analyses are socioeconomic status, FLG loss
of function genetic variants, maternal smoking, maternal and paternal eczema, birth order and
gender were included as confounders. To define social status variable we used a cluster of
parental occupation was reported at birth, number of children in the index child’s bedroom was
collected at age 4 years, and family income was ascertained at age 10 years [70].
Genotypes

For genotyping blood or saliva samples were collected from 1150 F1 generation
participants and DNA was extracted from these samples. FLG genotypes were assessed using
GoldenGate Genotyping Assays (Illumina, Inc, SanDiego, CA) on the beadXpressVeracode
platform (Illumina, Inc, SanDiego, CA) per Illumina’s protocol. Data were analyzed using the
genotyping module of the GenomeStudio Software package (Illumina, Inc, SanDiego, CA).
Individuals with minor allele for at least one of the FLG variants R501X, S3247X , or 2282del4
were classified as having the filaggrin haploinsufficiency [15].
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DNA methylation analysis

In the F1 generation at age 10 years DNA was extracted from whole blood, from a
subsample of 330 participants (F1) using a standard salting out procedure. Additionally, blood
was collected on dried blood spots in 724 neonates in the F1 generation and DNA was isolated
from these blood spots using a method based on the procedure described by Beyan et al [97].
DNA was extracted from cord blood from subsample of 193 samples in the F2 generaiton. Qubit
quantitation was used to determine the DNA concentration. Bisulfite-treatment for cytosine to
thymine conversion of one microgram DNA was performed using the EZ 96-DNA methylation
kit (Zymo Research, CA, USA), following standard protocol by the manufacturer. Epigenomescale DNA methylation was assessed using two arrays; the Illumina Infinium
HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA, USA), which interrogates
>484,000 CpG sites, and the Illumina Infinium MethylationEPIC BeadChip (Illumina, Inc., San
Diego, CA, USA), which interrogates > 850,000 CpGs associated with over 24,000 genes. The
data preprocessing and quality control steps are described below:

F1 generation
Guthrie card methylation data
Methylation data from F1 generation were present in total 8 batches - two from 450k and
rest are from EPIC array platform. The quantile normalized beta values are pre-processed and the
quality control is performed using the CPACOR pipeline [98]. Since the feature numbers are
varying in different batches in EPIC arrays, we pre-processed them separately and then
combined with pre-processed 450k array sapmles. Only the shared probes between EPIC and
450k arrays were only chosen. Batch effect has been removed using ComBat [99] in combined
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dataset. We excluded from analyses any CpGs which had probe-SNPs within ten base pairs and
with minor allele frequency (MAF) greater than 0.007 (which represented about 10 subjects in
expectation in the complete study cohort). Finally, we have the methylation information of
302700 number of sites in 724 participants.
Age 10 methylation data
For the methylation data of age 10 years, CPACOR pipeline was used for quality control
and and pre-processing the quantile normalized beta values [98]. At age 10 years we have
methylation data in total of 7 batches – two from 450k and five from EPIC array platform. We
combined samples from the two above mentioned array platforms and batches. We only used the
probes which were commonly present in EPIC and 450k arrays were only chosen. ComBat [99]
has been used to correct for batch effect. Any CpGs with probe-SNPs within ten base pairs and
with minor allele frequency (MAF) greater than 0.007 were not included in the analyses. Finally,
we have 349455 CpGs from 330 participants.

F2 generation
Cord blood methylation data
The QC and pre-processing has been done using CPACOR pipeline [98]. These are beta
values were generated after doing quantile normalization and background subtraction. Two
different runs was performed for 130 samples, from six different batches, in 450k platform and
63 samples from EPIC platform respectively. One sample from 450k array was discarded due to
maternal blood contamination. These two groups have been combined and only the shared
probes between 450k and EPIC have been taken. Further the data has been batch corrected using
ComBat [99]. CpG sites with probe-SNPs within ten base pairs and with minor allele frequency
34

(MAF) greater than 0.007 were excluded from analyses. Finally, we have 365697 of sites from
192 number of samples.

Cell Type proportions: White blood cell count for the Guthrie card methylation data (F1
generation) were generated from the three original groups (EPIC samples with 2 different chip
design and 450k samples). The estimateCellCounts() function of Minfi package [100] with
reference panel from Bakulski et al. 2016 [101] has been to generate cell proportion. Then the
cell counts of the three groups were combined together. Similarly for 10 year old samples (F1
generation) white blood cell counts were generated in the separate platform batches (450k and
EPIC) and then combined. The estimatecellcounts() function in minfi with the default settings
using reference panel from Houseman et al. 2012 [102] were used for age 10 year cell count.
For F2 generation cord blood samples same method mentioned for F1 generation Guthrie card
samples has been used. The cell counts have been generated separately for the 450k and EPIC
array samples and then later combined.

Statistical analysis
We record the methylation levels of each CpG as beta (β) value that ranges between zero
and one. Beta value is the proportion of methylated (M) over methylated (M) plus unmethylated
(U) probes (β=M/[c+M+U], with constant c being a constant to prevent diving by zero. For
analyses purposes, M-values i.e., logit-transformed β values (M-values, approximated by log2(β
/ (1-β)) are preferred because β values close to 0 or 1 tend to suffer from severe
heteroscedasticity [103]. In our analyses, we regressed the M-values n the cell types and calcuted
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the cell type residuals of DNA-M which is free from the cell type effects. These cell type
residuals were used throughout the analyses.

To have a clear predictive time order between duration of breastfeeding, DNA-M at
age10 and eczema age 18 years, and to avoid DNA-M at age 10 years being influenced by
eczema at age 10 years, we included only those participants were eczema free at age 10 years
(n=276). Eczema at age 18 thus either presents a re-occurrence of eczema (eczema in childhood
but not at age 10) or the first occurrence of eczema. The statistical analysis is divided into the
following two stages: (i) Identification of informative CpGs at age 10 years that are linked to
breastfeeding and eczema at age 18 years using a hierarchical screening approach (Figure 3). (ii)
Structural equational modelling to assess the indirect effect of breastfeeding on eczema at age 18
via methylation at age 10 years of CpGs identified in step (i). Since DNA methylation is
influenced by cell type compositions [104], the residual DNA-M after regressing out the cell
type proportions were used in all steps.
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349455 CpGs
(Residual DNA methylation
after adjusting for cell types)
n=251

Screening*
(a) Association of
breastfeeding duration with
DNA-M at age 10 years

Linear regression
14,849 CpGs

(b) Association of
DNA-M at age 10
years in eczema-free
children with eczema
at age 18 years

Log linear regression
839 CpGs associated at α= 0.05, 21 survive FDR
(n=276)

(c) Appropriate directionality
of association

17
Cp
Gs

(d) Inspect for outliers affecting
the associations:
(i) Breastfeeding duration and DNA-M at age 10
(ii) DNA-M at age 10 and eczema at age 18
(e) Confounding assessment
between the associations of :
(i) Breastfeeding duration and DNA-M
(ii) DNA-M and eczema at age 18

Structural equation modelling
assessing the indirect effect of
breastfeeding duration on
eczema at age 18 via DNA-M at
age 10 years at α=0.05.

12
Cp
Gs

11 CpGs

Stage (i)

4 CpG (α<=0.05)

Stage (ii)

All 11 CpGs (α<=0.1)

Figure 3. Flow of analyses to identify CpGs at age 10 years that potentially mediate
the protective effect of duration of breastfeeding on eczema at age 18. years
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The analyses are described in detail below:
(Stage i) Identification of informative CpGs at age 10 years using a hierarchical screening
method in the eczema-free at age 10 years (F1 generation) (Figure 3):
Of the 276 children analyzed, 251 had complete information for duration of breastfeeding
in weeks. In step (a) of the screening, 349,455 CpGs at age 10 years were tested for association
with breastfeeding duration using linear regression (Figure 3). In the next step, with the
statistically significant (α≤0.05) CpGs from step (a), we assessed their association with eczema
at age 18 years using log-linear regression adjusting for multiple testing by controlling false
discovery rate (FDR) at 0.05. CpGs which survive multiple adjustment (FDR≤0.05) in step (b),
were passed on to step (c). In step (c), in order to identify CpGs that could potentially mediate a
protective association we selected those CpGs whose methylation was positively associated with
duration of breastfeeding, and negatively associated with eczema at age 18 years, or vice versa.
For instance, if longer breastfeeding increases the methylation of a CpG and higher methylation
of this CpG is associated with lower risk of eczema, then this CpG will be selected. Hence, to
mediate protective effect, the selected CpGs should be significantly associated with
breastfeeding duration and eczema in opposite directions. The CpGs that pass step (c) werev then
examined for presence of outliers in their distributions, which could influence the associations
(step (d)) by checking the regression fit plots, and if present outliers were removed. The CpGs
that still showed a significant association with duration of breastfeeding and with eczema were
was more stringently assessed with confounders in step (e). Potential variables that may
confound the association between breastfeeding duration and DNA-M were added in the linear
regression models separately for each of the selected CpGs. Similarly, potential confounders
were added in the log-linear regression models assessing the association between DNA-M and
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eczema at age 18 separately for each CpG. Several genetic and clinical confounders, such as
maternal and paternal history of eczema, birth order of the child, filaggrin (FLG) loss of function
genetic variants, socioeconomic status, and maternal smoking were included. Confounders that
change the observed effect sizes in regression models by more than 10% were retained in the
model. The CpGs that were still significantly associated after retaining such confounders were
qualified for the stage (ii) of the analyses (Figure 3).
(Stage ii) Structural equation modelling:
To distinguish the direct, indirect, and total effect of breastfeeding on eczema via DNA
methylation of CpGs selected in stage (i) we performed structural equation modelling. Separate
path models were fitted for each of the CpGs including the relevant confounders using maximum
likelihood estimation with robust standard errors.
To substantiate the role of the duration of breastfeeding in altering the methylation level
of the above identified CpGs at 10 years of age, we utilized methylation data obtained prior to an
established breastfeeding effect collected within a week of birth using heel sticks (obtained from
dried blood spots on Guthrie cards) in the F1 generation. We inspected whether duration of
breastfeeding can explain the variability in DNA-M at age 10 that is not explained by DNA-M
obtained from Guthrie cards. To this end, using the selected CpGs from stage (ii) of the analyses,
we ran a linear regression with DNA-M at age 10 years as the response and DNA-M from
Guthrie cards and duration of breastfeeding as predictors (n= 172).

In addition, the selected CpGs identified in the F1 generation data were also examined in
F2 generation (n=192) using cord blood methylation to assess their association with eczema in
infancy prior to the initiation of breastfeeding.
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The screening steps involving linear and log linear models was performed using the lm()
and glm() functions in R (R package 3.1.1 version). Path analyses were implemented using
Mplus Version 7, and the remaining analyses with the selected CpGs were performed using SAS,
Version 9.4 (SAS Institute, Cary, NC, USA).

Results
We found no significant differences in the proportion of eczema prevalence, duration of
breastfeeding, gender, maternal smoking during pregnancy, socioeconomic status, filaggrin loss
of function mutation, and maternal and paternal eczema assessed during pregnancy between the
whole cohort (N=1294) and those with DNA-M information at age 10 (n=276) (Table 4).

Focusing on eczema-free children at age 10 years (n=276), in step (a) of the hierarchical
screening (Figure 3, Table 5), we tested the association of duration of breastfeeding with
epigenome-wide DNA-M at age 10 years. Out of the 349,455 CpGs tested, 14,849 were
significantly associated with duration of breastfeeding at α≤0.05. In the second hierarchical step
(b) the 14,543 breastfeeding associated CpGs were tested for an association with eczema at age
18. We found 839 CpGs to be associated with eczema and we corrected for FDR at this step. 21
CpGs survived multiple testing adjustments using FDR. In step (c), 17 out of the 21 were found
to have an appropriate directionality; however, 5 of these were not significantly associated with
breastfeeding duration and eczema after removing outliers in step (d). The remaining 12 CpGs
were then tested for confounding in the next step (e). Gender, socioeconomic status, maternal
smoking during pregnancy, and maternal and paternal eczema were added as potential
confounders in linear regression assessing the association between breastfeeding duration and
DNA-M. For the association of DNA-M and eczema at age 18, all the above confounder and
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FLG loss of function and birth order were added in the log-linear model. On retaining the
confounders that change the observed effect sizes in regression models by more than 10%, 11 of
these 12 still remained significantly associated with both duration of breastfeeding and with
eczema, respectively (Figure 3, Table 5).

Of the eleven CpGs that pass the screening, the methylation of cg03605610 (intergenic),
cg04708216 (intergenic), cg04928096 (AXIN1), cg015854022 (intergenic), cg26375057 (ZIC1),
cg26979504 (HHEX), cg04994084 (intergenic), cg24408469 (CELSR1), and cg27215578
(intergenic) were positively associated with duration of breastfeeding and negatively with
eczema at age 18 (Table 5). Whereas the methylation of cg02054493 (PTRH1), and cg25311764
(GCNT3) were negatively associated with duration of breastfeeding and positively with eczema
at age 18 years (Table 5).

In stage (ii), structural equation modelling was conducted with each of the eleven CpGs
that were selected in stage (i) of analyses (Table 5) with participants who were eczema free at
age 10 years (n=276). The indirect effect of breastfeeding duration on eczema at age 18 years
mediated through DNA-M, the direct effect and total effect (combination of direct and indirect)
were estimated. Each of the 11 selected CpGs, were separately analyzed using structural
equational modelling to test whether the protective effect of breastfeeding is mediated via these
CpGs on eczema at age 18 years. Four CpGs cg03605610 (intergenic), cg04928096 (AXIN1),
cg26375057 (ZIC1), and cg26979504 (HHEX), tested individually were in the causal pathway
between duration of breastfeeding and eczema at age 18 years.
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Table 4. Comparison of population characteristics between the whole cohort and those with
DNA methylation at age 10 years.
Sample with
Covariates
Whole cohort DNA-M at age
10 years
N =1294
n=276
N (%)
n (%)
p-value
0.25
Maternal smoking during pregnancy
Yes
300 (23.2)
55 (19.9)
No
989 (76.4)
219 (79.3)
Missing
5 (0.39)
2 (0.7)
0.07
Eczema at age 18
Yes
157 (12.1)
23 (8.3)
No
1131 ( 87.4)
253 (91.6)
Missing
6 (0.46)
0.06
Sex
Boys
644 (49.7)
155 (56.2)
Girls
650 (50.2)
121 (43.8)
0.97
Socio economic status
High
102 (7.9)
24 ( 8.7)
Medium
937 (72.4)
209 (75.7)
Low
176 (13.6)
41 (14.8)
Missing
79 (6.1)
2 (0.7)
0.43
Filaggrin loss of function variants
Yes
107 (8.3)
22 (8.0)
No
968 (74.8)
241 (87.3)
Missing
219 (16.9)
13 (4.7)
0.84
Maternal eczema during pregnancy
Yes
160 (12.4)
33 (12.0)
No
1124 (86.9)
241 (87.3)
Missing
10 (0.8)
2 (0.7)
0.31
Paternal eczema during pregnancy
Yes
90 (6.9)
24 (8.7)
No
1186 ( 91.6)
249 (90.2)
Missing
18 (1.4)
3 (1.1)
0.30
Birth Order
1
469 (36.2)
105 (38.04)
2
362 (30)
80 (30)
3
262 (20.2)
71 (25.7)
Missing
201 (15.5)
20 (7.25)
Median (p5, p95)
8.0 (0, 40)
12.0 (0, 40)
0.06
Duration of breastfeeding (weeks)
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Table 5. Adjusted association of cell type residuals of CpGs with duration of breastfeeding and eczema at age
18. Participants with eczema at age 10 years were excluded from the analyses (n=276). The associations that
include confounders from the screening step are marked, and these confounders were also included in the path
analyses. For the rest, no confounder changed the assocition by more than 10%. The indirect effect is determi
ned in the stage (ii) in path analyses (duration of breastfeeding  CpG  eczema at age 18). Only significant
indirect effects are shown.
Indirect effect of
Association between
Association between
duration of
duration of breastfeeding
DNA-M at age 10 and
breastfeeding on
and DNA-M at age 10
eczema at age 18
eczema at age 18
(n=251)
(n=276)
via DNA-M
Ilmnid
Gene names
Estimate
p-value Risk ratio
pvalue
Estimate p-value
cg02054493
PTRH1
-0.003
0.02
6.9
0.0005*
cg03605610
0.006
0.01
0.324
3.59E-05
-0.008
0.02
α
cg04708216
0.002
0.03
0.015
<.0001
cg04928096
AXIN1
0.004
0.01
0.224
2.32E-06
-0.008
0.049
β
cg15854022
0.001
0.02
0.002
<.0001*
cg26375057
ZIC1
0.005
0.03
0.301
3.09E-05
-0.008
0.034
cg26979504
HHEX
0.005
0.01
0.301
5.23E-05
-0.007
0.021
cg04994084
0.005
0.04
0.3927
<.0001
cg24408469
CELSR1
0.003
0.01
0.096
0.0017β
cg25311764
GCNT3
-0.002
0.03
27.4
<.0001 α # β
cg27215578
0.005
0.03
0.4
0.0048
Adjusted for *gender # socioeconomic status α fillagrin loss of function mutation βbirth order
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All four CpGs were positively associated with duration of breastfeeding and negatively
with eczema at age 18 years in the screening. In other words, longer duration of breastfeeding
was associated with higher DNA-M of cg03605610 (Estimate: 0.006, p-value: 0.01),
cg04928096 (AXIN1) (Estimate: 0.004, p-value: 0.01), cg26375057 (ZIC1) (Estimate: 0.005, pvalue: 0.03) and cg26979504 (HHEX) (Estimate: 0.005, p-value: 0.01). Higher DNA-M was in
turn, associated with lower risk of eczema for cg03605610 (Risk ratio: 0.3, p-value: 3.59E-05),
cg04928096 (AXIN1) (Risk ratio: 0.2, p-value: 2.32E-06), cg26375057 (ZIC1) (Risk ratio: 0.3, pvalue: 3.09E-05) and cg26979504 (HHEX) (Risk ratio: 0.3, p-value: 5.23E-05) (Table 5, Figure
4).
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A

(i)

(ii)

(iii)

Figure 4. Association of cell type residuals of DNA-M with breastfeeding duration and eczema at age 18 years. CpGs that mediate the
protective effect are shown: (A) cg03605610 (B) cg04928096 (AXIN1) (C) cg26375057 (ZIC1) (D) cg26979504 (HHEX). The panels
are described as follows: (i) path analyses showing the indirect effect of breastfeeding duration via DNA-M of CpGs on eczema at age
18 years; (ii) Association of DNA-M at age 10 years with duration of breastfeeding; (iii) Association of DNA-M at age 10 years with
eczema at age 18 years.
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B

(i)

(ii)

(iii)

Figure 4. (Continued): Association of cell type residuals of DNA-M with breastfeeding duration and eczema at age 18 years.
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C
(i)

(ii)

(iii)

Figure 4 (Continued): Association of cell type residuals of DNA-M with breastfeeding duration and eczema at age 18 years.
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D
(i)

(iii)

(ii)

Figure 4 (Continued): Association of cell type residuals of DNA-M with breastfeeding duration and eczema at age 18 years.
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In the path analyses in stage (ii), the significant indirect effect indicates that longer
duration of breastfeeding showed a protective effect on eczema at age18 (Estimate: -0.008, pvalue: 0.022 for cg03605610; Estimate: -0.008, p-value: 0.049 for cg04928096 (AXIN1);
Estimate: -0.008, p-value: 0.034 for cg26375057 (ZIC1); Estimate: -0.007, p-value: 0.021 for
cg26979504 (HHEX)) (Table 5, Figure 4).

The mean methylations of the four CpGs are presented in Table 6. Whereas cg03605610
is an intergenic CpG between NRC2 (NK Cell-Activating Receptor) and Long Intergenic NonProtein Coding RNA 1276, cg04928096 (AXIN1) is located on the 3’UTR. The CpG
cg26375057 is located in the first exon of the ZIC1 gene. Longer duration of breastfeeding is
associated with a higher methylation of all these CpGs, which are in turn, linked to a lower risk
of eczema (Figure 4).
Table 6. Distribution of beta values, M-Values, and cell type residuals of DNA-M (n=276)
Ilmnid
DNA methylation
Mean
Median
Std Dev 5th Pct 95th Pct
Beta value
0.10
0.10
0.03
0.06
0.17
M
value
-3.17
-3.11
0.51
-4.07
-2.31
cg03605610
Cell type residual -4.25E-16
0.04
0.50
-0.88
0.80
0.90
0.90
0.03
0.85
0.93
Beta value
3.18
3.20
0.42
2.49
3.80
cg04928096
M value
Cell type residual 4.70E-16
-0.01
0.40
-0.66
0.64
Beta value
0.08
0.08
0.03
0.05
0.13
cg26375057
M value
-3.58
-3.59
0.51
-4.40
-2.72
Cell type residual -5.00E-16
-0.01
0.50
-0.80
0.79
Beta value
0.03
0.03
0.01
0.02
0.04
cg26979504
M value
-5.16
-5.14
0.45
-5.92
-4.51
Cell type residual -7.08E-16 -2.51E-03
0.44
-0.74
0.64
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To substantiate the role of breastfeeding on these CpGs at age 10 years, we utilized their
methylation before initiation of breastfeeding (obtained right after delivery, or within a week
from heel sticks) and after breastfeeding (obtained at age 10 years) (n=172). We ran a linear
regression with age 10 DNA-M as the outcome and DNA-M obtained from Guthrie cards as the
predictor. We found that duration of breastfeeding was significantly associated (α≤0.05) with
DNA-M of cg03605610, cg04928096 (AXIN1), and cg26979504 (HHEX) and marginally (pvalue =0.11) with cg26375057 (ZIC1) (Table 7). This indicates that duration of breastfeeding
explained the variability of DNA-M at age 10 of these CpGs that is not explained by DNA-M
from Guthrie cards. The direction of association was positive for all four CpGs, thus
strengthening our findings that longer duration of breastfeeding is linked to higher DNA-M at
age 10 years.
Further, to ensure that it is the breastfeeding-associated methylation of these CpGs
mediates the effect on eczema, we tested in the F2 generation whether cord blood methylation of
these CpGs obtained prior to breast feeding initiation can explain eczema in infancy in the F2
generation (n=192). None of the other CpGs were associated with eczema at infancy (Table 7).
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Table 7. Association of duration of breastfeeding with DNA-M in F1 generation and
DNA-M and eczema in F2 generation. (A) Assessing whether duration of breastfeeding
explains variability of DNA-M at age 10 (post breastfeeding) in addition to that of
DNA-M prior to breastfeeding from Guthrie cards (collected at birth or within a week
of birth) (B) Association of cord blood DNA-M
with eczema in infancy in F2 generation. Cell type residuals of DNA-M are used
throughout the analyses.
(A)
(B)
F1 generation
F2 generation
Association of DNA-M from Guthrie
Association of
card (collected at birth or within a week
cord blood
of birth) and duration of breastfeeding
methylation with
with DNA-M at age 10
eczema in infancy
(n=172)
(n=192)
Risk
Ilmnid
Parameter
Estimate p-value
p-value
ratios
Guthrie DNAM
0.3
<.0001
1.02
0.95
Duration
of
cg03605610
breastfeeding
0.008
0.002
cg04928096
(AXIN1)

Guthrie DNAM
Duration of
breastfeeding

cg26375057
(ZIC1)

Guthrie DNAM
Duration of
breastfeeding

cg26979504
(HHEX)

Guthrie DNAM
Duration of
breastfeeding
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-.04

0.66

0.006

0.007

-.03

0.60

0.004

0.11

0.04

0.56

0.005

0.049

0.48

0.06

0.74

0.36

1.30

0.31

Discussion
Our results demonstrate that the protective effect of longer breastfeeding duration on
eczema at age 18 can be mediated via DNA methylation of four CpGs: cg03605610 (intergenic),
cg04928096 (AXIN1), cg26375057 (ZIC1), cg26979504 (HHEX).

Presence of eczema at age 10 years will be associated with eczema at age 18, and also
affect DNA-M at age 10 years, driving the association of DNA-M at age 10 years predicting
eczema at age 18 years. To rule out this possibility, we performed the analyses focusing on
participants without eczema at age 10 years (n=276). To identify potential CpGs at age 10 years
that mediate the protective effect of duration of breastfeeding on eczema at age 18 years we
performed a screening with several hierarchical steps (stage (i)). The informative CpGs (related
to breastfeeding and eczema) that passed the screening step were analyzed using structural
equational modelling (stage (ii)) to test mediation. The structural equational modelling focused
on these 276 participants showed that the CpGs cg03605610 (intergenic), cg04928096 (AXIN1),
cg26375057 (ZIC1), and cg26979504 (HHEX) were in the causal pathway mediating the
protective effect of longer breastfeeding duration on eczema at age 18.

There are several limitations in this study. Firstly, the association of duration of
breastfeeding with DNA-M at age 10 years for all the four identified CpGs in the pathway
between breastfeeding and eczema at age 18 years is small. However, the importance of small
changes in methylation of a mixture of white blood cells associated with exposures and complex
human diseases are now being recognized [105, 106]. Nevertheless, to investigate these ‘small
effects’, we tested the impact of duration of breastfeeding on methylation in two steps. First, in
the F1 generation we utilized methylation levels collected prior to breastfeeding initiation (after
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delivery from heel stick blood) and that collected at age 10 years (n=172). We assessed whether
duration of breastfeeding can explain additional variability in age 10 DNA-M that is not
explained by DNA-M collected soon after birth from Guthrie cards. Second, in the F2 generation
we tested whether methylation obtained after delivery from cord blood prior to breastfeeding
initiation can explain eczema in the first year of life (n=192).

In the F1 generation, we ran a linear regression separately for each of the four CpGs, with
DNA-M at age 10 years as outcome, and DNA-M from Guthrie cards and duration of
breastfeeding as predictors. For the CpG cg03605610, DNA-M obtained after birth from Guthrie
card explained the variability of DNA-M at age 10 years. Additionally, duration of breastfeeding
also explained the variability in DNA-M at age 10 years for cg03605610, such that longer
duration was linked to higher methylation. For the other CpGs, DNA-M from Guthrie card was
not associated with DNA-M at age 10 years. However, duration of breastfeeding explained the
variability of DNA-M at age 10 of these CpGs that is not explained by DNA-M from Guthrie
cards. Longer duration of breastfeeding linked to higher methylation of cg04928096 (AXIN1),
cg26979504 (HHEX) (p-value ≤0.05), and cg26375057 (ZIC1) (p-value≤0.1) (Table 7). These
results indicate that methylation changes of these CpGs are indeed related to longer
breastfeeding duration. In the F2 generation, cord blood methylation collected prior to
breastfeeding initiation of none of the CpGs were associated with eczema, supporting the
findings in the F1 generation regarding mediation of the breastfeeding effect via these CpGs on
eczema at age 18 (Table 7).

Apart from the above, measurement error is unlikely since the Illumina Infinium
HumanMethylation850 beadchip array, is known to have high reliability and reproducibility
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[107]. Since information regarding duration of breastfeeding was collected at year one and two,
it can be considered reliable with minimal recall bias [77]. Information regarding eczema was
acquired from detailed questions during clinical visits. Eczema was defined following the
Hanifin and Rajka criteria minimizing misclassification [69, 76].

In addition to the above, we also investigated the pattern of eczema at ages 1-2 years and
4 years in our sample analyzed (n=276, eczema free at age 10 years). There were six participants
who had eczema in either age 1-2 or age 4 or both, with remission at age 10 and re-occurrence at
age 18 years. It is likely that these participants were misclassified to be eczema free at age 10
years. To avoid any such misclassification of eczema at age 10 years, we excluded these six
participants. However, the associations of CpGs with eczema and breastfeeding duration were
still significant.

The main strength of the study is clear predictive time order with duration of
breastfeeding preceding age 10 methylation followed by the eczema that occurs at age 18 years,
ruling out the possibility of reverse causation. To exclude the influence of eczema at age 10 on
the association between DNA-M at age 10 years and eczema at age 18, we have considered only
eczema free participants at age 10 years (n=276). The CpGs cg03605610 (intergenic),
cg04928096 (AXIN1), cg26375057 (ZIC1), cg26979504 (HHEX) were in the causal pathway
between breastfeeding duration and eczema at age 18. We also took into account the various cell
types that influence DNA-M by using the residual methylation values calculated by regressing
the DNA-M on the cell types at all time points in the analyses.

There are only a few studies that have explored the association between breastfeeding
and DNA-M [51]. Obermann-Borst et al, reported a decrease in the LEP (leptin) gene promoter
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at age 1.4 years with increasing duration of breastfeeding categories (-0.06, 95% CI: -1.19, 0.01), however, methylation was ascertained at the same time as breastfeeding, failing to
establish a clear time order [93]. In a case-only-study of breast cancer patients, a higher odds
ratio of CDKN2A promoter methylation status (Yes/No) in breast tumor tissue was found in
never breastfed women (OR: 2.75, 95% CI: 1.14, 6.62) in the premenopausal group [95]. SotoRamirez, found an interaction of breast duration with the genetic variants on the methylation of
the 17q12 region of the chromosome [94]. In animal studies, the promoters of Nyp and Slc2a4
were differentially methylated in rats fed with breastmilk compared to formula [108, 109].

With respect to eczema, there seveal reports describing assocaiation of methylation of
FLG [110], TSLP and FCER1G [111], and PROZ and NEU1 [112] with eczema. However, many
of these studies have used concurrent measurements of DNA-M and outcome, making it difficult
to distinguish between DNA-M predicting to eczema and DNA-M modified as a result of
eczema. We demonstrate for the first time that DNA-M at age 10 years of cg03605610
(intergenic), cg04928096 (AXIN1), cg26375057 (ZIC1), and cg26979504 (HHEX) may mediate
the protective effect of a longer duration of breastfeeding on eczema at age 18 years.

Regarding these four CpGs, since higher methylation in the promoter and first exon
methylation downregulates to lower gene expression [44, 113]; it implies that longer
breastfeeding could be associated with lower expression cg26375057 (ZIC1). The CpG
cg26979504 (HHEX) is in the body region of the gene and CpG cg04928096 (AXIN1) is in the
3’UTR region. Although the role of methylation in the body region and 3’UTR is not completely
understood [114], body region methylation is known to modify transcriptional efficiency [44],
and 3’UTR methylation may also regulate gene expression [115].
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The genes of these four CpGs are considered functionally relevant with regard to
breastfeeding and eczema in several animal and human studies. The AXIN1 (Axis Inhibition
Protein 1) gene is a part of the Wnt signaling pathway and induces the ubiquination and
degradation of cytosolic β-catenin [116]. β-catenin is involved in cell–cell adhesion by
interacting with cadherin proteins and its degradation may lead to apoptosis of cells [117].
Ablation of β-catenin in epidermis has been reported to lead to barrier dysfunction indicating its
role in epidermal function [118], thus corroborating our findings of higher methylation for the
CpG of AXIN1 associated with lower risk of eczema. No direct association is reported in the
literature regarding breastfeeding duration and the AXIN1 gene. However, it is known that
Epidermal Growth Factor (EGF), a ligand of Epidermal Growth Factor Receptor is abundant in
breastmilk [119]. Studies have demonstrated that ligand activated EGFR leads to
phosphorylation of several downstream proteins leading to transfer of Axin complexed with
other proteins (GSK3-APC-Axin complex)[120] to the cell membrane, thus promoting the
stabilization of β-catenin[120]. EGF in breastmilk may also inactivate GSK3 (glycogen synthase
kinase 3) and stabilize β-catenin [119].

HHEX (Hematopoietically Expressed Homeobox) codes for a transcription factor that is
involved in several developmental and differentiation processes including that of the mammary
epithelial cells [121]. Puppin et al have reported that higher nuclear localization of HHEX in
lactating tissue compared to normal non-lactating human breast tissue [121]. Kothapalli et al
found a higher expression of HHEX in the cerebral cortex region of baboons who were fed
higher amounts of Docosahexaenoic acid (DHA) than controls [122] indicating a possible link
between fatty acids found in breast milk with HHEX expression. Additionally, lower expression
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of HHEX was reported in dermal mesenchymal stem cells in psoriatic skin lesions compared to
controls [123] implying its role in inflammatory skin disease.

The ZIC1 (zinc finger in the cerebellum 1) gene produces a transcriptional activator and
is involved in neurogenesis [124], and is a classic marker of brown adipose tissue (BAT) [125]
which is present in breast tissue [126]. An in-vitro analysis with mice adipose cells reported that
DHA synthesis takes place in the BAT cells [125]. Zic1 is important for maintaining the
expression of retinoic acid (RA)-degrading enzyme cyp26a1 in the forebrain of zebrafish, with
Zic1 loss of function linked to higher the levels of RA [127]. Interestingly, RAs play a crucial
role in the maintenance of epithelial tissues and retinoic acid isomers are also used as drugs to
treat several dermatological diseases [128] including eczema [129].

The CpG cg03605610 is an intergenic CpG on chromosome 6 lying between the genes
NRC2 (NK Cell-Activating Receptor) and Long Intergenic Non-Protein Coding RNA 1276.
NRC2, also known NKp44 is an NK cell activating receptor [130] is implicated in psoriatic
inflammation [131]. Lesional skin and peripheral blood of psoriasis patients have a high
proportion of innate lymphoid cells expressing this receptor (NKp44 ++ ILC3) which also
produce the IL22, a cytokine that triggers epidermal thickening in psoriatic skin [131]. Long
non-coding RNAs (lncRNAs) produce transcripts over 200 nucleotides in length, which do not
translate in to proteins [132]. They are found encapsulated in extracellular vesicles of breastmilk
[132] playing a role in the regulation of gene expression [133] and are linked to actinic
dermatosis [134] and psoriasis [135].

Although peripheral blood methylation of the detected genes is relevant with respect to
eczema, it remains an open question whether peripheral blood methylation can be used as a
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substitute for tissue specific genes. Interestingly, these genes are expressed not only skin, but
also several other tissues including in whole blood (www.genecards.com). Additionally, several
studies have found similar methylation of specific genes in blood and other organs [136, 137],
reinforcing that whole blood methylation can reflect the methylation pattern of specific tissues.
To summarize, the genes of the detected methylation sites are associated with fatty acids,
cell–cell adhesion, apoptosis, and retinoic acid signaling pathway, providing an insight regarding
their role in eczema pathogenesis linked to breastfeeding exposure. This is the first study to
demonstrate that DNA-M potentially mediates the effect of breastfeeding on eczema reinforcing
the importance of breastfeeding. Additionally, our results also demonstrate a long-term effect of
duration of breastfeeding on DNA-M at age 10. Methylation of these CpGs may be utilized as
target based markers that predict eczema and can be modified by longer breastfeeding thus
preventing the disease. Future studies are needed to replicate our findings. In addition, there is a
need to understand how the breastmilk composition influences the methylation of genes. This
information may aid to develop therapeutic/preventative targets for eczema.
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CHAPTER 4
INTERACTION OF GESTATIONAL SMOKING AND DURATION OF BREASTFEEDING
ON DNA METHYLATION LINKED TO LOWER RISK OF ECZEMA AT AGE 18 YEARS.

Abstract
Rationale: Studies regarding the association of breastfeeding duration and gestational smoking
with eczema report contradictory findings. We hypothesize that combined effect of breastfeeding
duration and gestational smoking is associated with DNA-M, which is in turn is then linked to
eczema.
Methods: Peripheral blood samples were collected at age 10 years. Gestational smoking,
breastfeeding duration information, and eczema at age 18 years were obtained during follow ups
after birth at 1, 2, and at 18 years, respectively. DNA-M of CpG (cytosine-phosphate-guanine)
sites was assessed using the Illumina HumanMethylation450K and 850K BeadChips. In
hierarchical screening steps, we identified CpGs at age 10 years associated with interaction of
breastfeeding duration and gestational smoking at at p-value of α≤0.05 (linear regression) and
with eczema at age 18 years using log-linear regression followed by multiple testing adjustment
(FDR p-value<=0.05). To identify protective CpGs at age 10 years, we selected those that have
opposite direction of association with interaction of breastfeeding duration and gestational
smoking, and with eczema at age 18 years, respectively, adjusting for relevant confounders. To
eliminate reverse causation by eczema at age 10 years influencing the DNA-M at age 10 years
we excluded children with eczema at age 10 years (n=276).
Results: The combined effect of gestational smoking and duration of breastfeeding influenced
the DNA-M at age 10 years of cg07208825 (ALMS1P), cg12954512 (Intergenic), and
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cg21601919 (FGF18) such that they predict a lower risk of eczema at age 18 years. Conclusion:
DNA-M related to combined effect of gestational smoking and breastfeeding duration is linked
to a lower risk of eczema, constituting a mediation between these risk factors and eczema.

Background
Eczema is a chronic inflammatory disease characterized by itching and inflammation of
the skin [1]. Eczema in early life may progress to other diseases such as food allergy, allergic
rhinitis, asthma, known as atopic march [53] leading to increased health care costs and loss of
quality of life [7]. Eczema is considered as a Th2 mediated disease [138] and has a complex and
multifactorial pathogenesis. It can be genetically inherited and genetic variants of several genes
have been associated the disease [139]. The most widely replicated genetic factor is “loss of
function (LOF)” mutation of the filaggrin (FLG) gene [10, 52] which is responsible for
aggregating keratin filaments and maintain the barrier function of the skin [140]. However,
presence of FLG LOF mutations explain less than 10% of the eczema cases [16].
Apart from the genetic factors, environmental factors such as gestational smoking and
breastfeeding duration may also play a role in immune system dysregulation and epidermal
barrier dysfunction leading to eczema. In a systematic review Kramer et al states that exclusive
breastfeeding for at least 3 months reduces the risk of atopic dermatitis in infancy [19]. A
randomized trial comparing an intervention with prolonged and exclusive breastfeeding, reported
that there was a 54% lower risk of flexural eczema at age 16 years in the intervention group
compared to those who received usual care [21]. Chiu et al found breastfeeding for more than 6
months was associated with a significantly lower risk of developing eczema at ages 1 and 2 years
[22].
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Some studies have also reported a protective effect of maternal smoking on eczema. A
large study based in Denmark showed lower odds of atopic eczema at ages 14-18 years if the
mother smoked during late pregnancy [27]. Another large cohort study found reduced odds of
eczema at 5 years of age in children whose mothers smoked during pregnancy [28]. Ek et al,
reported that maternal smoking around birth is associated with a lower odds of being diagnosed
with eczema in a large study of UK biobank data in participants ranging from ages 37 to 73 years
[29]. Interestingly, coal tar which has several components similar to tobacco smoke, has been
used as a topical remedy of eczema since ancient times [32]. Experimental studies have shown
coal tar improves barrier function by activating the activating the AhR/ARNT (Aryl hydrocarbon
receptor/ Aryl Hydrocarbon Receptor Nuclear Translocator) genes [33] which are also
responsible metabolizing cigarette smoke compounds [141].
Although the above studies have found breastfeeding and gestational smoking to be
protective of eczema, it is not yet known how breastfeeding and gestational smoking mediate
their effects. One possible mechanism by which breastfeeding may influence eczema is by
altering DNA methylation (DNA-M), an epigenetic mechanism that can change the gene
expression without mutation [40]. Findings suggest that the methylation of the 5′ carbon of
cytosine nucleotides at cytosine-phosphate-guanine (CpG) sites in the DNA is affected by
environmental exposures [41] and that early life exposures can have a long-term effect on DNAM [42]. A recent meta-analysis reported five human studies [51] linking breastfeeding duration
to methylation of the chromosome region 17q12, LEP (LEPTIN) gene, and also influencing
global methylation patterns [51]. Interestingly, regarding smoking multiple studies have
consistently reported methylation of the AHRR gene to be associated with maternal smoking
during pregnancy [47, 49, 142]. In a genome-wide Consortium Meta-analysis across 13 cohorts,
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several CpGs belonging to the biological processes such as nervous system development,
phosphate-containing compound metabolism, and cell to cell communication have been
identified in cord blood linked to maternal smoking during pregnancy [50].

Reports linking breastfeeding duration and gestational smoking to eczema have
conflicting results. If the mother smokes during pregnancy the offspring is exposed to smoke in
utero, and additionally components of smoke may be stored in the breast fat tissues and passed
on the child during breastfeeding [30, 31]. Till date, there has been no study investigating the
interplay of gestational smoking, breastfeeding duration, and DNA-M on eczema. We
hypothesize that gestational smoking and breastfeeding duration can jointly influence DNA-M of
CpGs such that they explain a lower risk of eczema. To this end, we analyzed data from the Isle
of Wight cohort, U.K. to identify methylation sites at age 10 years in peripheral blood that are
associated with combined effect of duration of breastfeeding and smoking during pregnancy.
Further, to extend the above time-order of risk and effects, we assess whether these CpGs at age
10 years are associated with eczema at age 18 years. We used a hierarchical screening approach
in participants who were eczema-free at age 10 years to identify whether the above CpGs are
linked to maternal smoking, duration of breastfeeding and eczema at age 18 years.

Methods
Study population
A population based birth cohort (n=1,536) was established in 1989 on the Isle of Wight,
UK, to prospectively study natural history of allergic conditions (F1 generation). From January
1989 to February 1990 1,536 F1-children were born on the Isle of Wight (IOW), among which,
1,456 F0-mother-F1-child pairs were enrolled into the cohort study after exclusion of perinatal
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deaths, adoptions, and refusals. Children were followed up at 1, 2, 4, 10 and 18 years of age. [96]
These F1 participants themselves became pregnant or fathered a child (F2-offspring), which was
enrolled in a follow-up study up.

The local research ethics committee (South Central - Hampshire B Research Ethics
Committee) and the Institutional Review Board of the University of Memphis approved the
study. Informed written parental or child’s consent (at age 18 years) were obtained for all
participants at recruitment and each follow-up. The IOW birth cohort has been described in
detail elsewhere [64-66].

Phenotypes

Information on eczema symptoms was acquired though detailed interviews and
examinations at the 10 and 18 year follow up. Eczema was defined according to the Hanifin and
Rajka criteria [68] as chronic or chronically relapsing, itchy dermatitis lasting more than 6 weeks
with characteristic morphology and distribution [69]. Regarding breastfeeding, the mother was
asked at the 1- and 2-year follow-up of the F1 generation whether the child was breastfed and the
total duration of breastfeeding (in weeks). Detailed questionnaires were completed for each child
at each follow-up. A postal or telephone questionnaire was sent if a visit was not possible [67].

Socioeconomic status, maternal and paternal eczema, FLG loss of function genetic
variants, maternal smoking, and gender were included as confounders. Parental occupation was
reported at birth, number of children in the index child’s bedroom was collected at age 4 years,
and family income was ascertained at age 10 years. These three variables were clustered to
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produce a family social status variable used in our analyses [70]. Gender, maternal smoking, and
maternal and paternal eczema were determined at birth.
Genotypes

FLG genetic variants were genotyped from the DNA samples were extracted from 1,150
cohort participants from blood or saliva and assessed using GoldenGate Genotyping Assays
(Illumina, Inc, SanDiego, CA) on the beadXpressVeracode platform (Illumina, Inc, SanDiego,
CA) per Illumina’s protocol. Data were analyzed using the genotyping module of the
GenomeStudio Software package (Illumina, Inc, SanDiego, CA). Individuals carrying the minor
allele for at least one of the FLG variants R501X, 2282del4, or S3247X were classified as having
filaggrin haploinsufficiency [15].

DNA methylation analysis

DNA was extracted from whole blood using a standard salting out procedure, from a
subsample of 333 10–year old samples (F1). Additionally, in the F1 generation DNA was
isolated from dried blood spots on Guthrie cards of 724 neonates using a method based on the
procedure described by Beyan et al [97]. In the F2 generation, DNA was extracted from cord
blood from subsample of 193 samples. DNA concentration was determined by Qubit
quantitation. One microgram of DNA was bisulfite-treated for cytosine to thymine conversion
using the EZ 96-DNA methylation kit (Zymo Research, CA, USA), following the manufacturer's
standard protocol.
Epigenome-scale DNA methylation was assessed using the Illumina Infinium
HumanMethylation450 BeadChip (Illumina, Inc., San Diego, CA, USA), which interrogates
>484,000 CpG sites, and the Illumina Infinium MethylationEPIC BeadChip (Illumina, Inc., San
64

Diego, CA, USA), which interrogates > 850,000 CpGs associated with over 24,000 genes. The
quality control and data preprocessing steps are described below:

F1 generation
Guthrie card methylation data
There are 8 total batches for the methylation data from F1 generation – two from 450k
and rest are from EPIC array platform. CPACOR pipeline [98] has been used for quality control
(QC) and pre-processing the quantile normalized beta values from the samples. Due to varying
feature numbers in different batches in EPIC arrays, we pre-processed them separately and
combined them with pre-processed samples from 450k array. These groups have been combined
and only the shared probes between EPIC and 450k arrays were chosen. ComBat [99] has been
used to remove the batch effect in combined dataset. Finally, we have 302700 number of sites
from 724 number of samples.
Age 10 methylation data
For 10 year samples, quality control was undertaken and quantile normalized beta values
were processed following the CPACOR pipeline[98] from total of 7 batches – two from 450k
and five are from EPIC array platform. These samples from different array platforms and
batches were combined and only the shared probes between EPIC and 450k arrays were only
chosen. ComBat [99] has been used to remove the batch effect in combined dataset. Finally, we
have 349455 number of sites from 330 samples.

Cell Type proportions: For Guthrie card methylation data, white blood cell counts were
generated from the three original groups (EPIC samples with 2 different chip design and 450k
samples), and then combined together. The estimateCellCounts() function from Minfi package
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[100] has been used, using reference panel from Bakulski et al. 2016 [101], to generate cell
proportion. For 10 year old samples (F1 generation) white blood cell counts were generated
originally in the separate platform batches (450k and EPIC) and then combined. This method
used the estimatecellcounts() function in minfi with the default settings using reference panel
from Houseman et al. 2012 [102].

Statistical Analyses
Methylation levels for each CpG site were recorded as beta (β) values, which represent
the proportion of methylated (M) over methylated (M) plus unmethylated (U) probes
(β=M/[c+M+U], with constant c being a constant to prevent diving by zero. M-values or logittransformed β values (M-values, approximated by log2(β / (1-β)) were calculated since β values
close to 0 or 1 tend to suffer from severe heteroscedasticity [103]. CpG sites with probe-SNPs
within ten base pairs and with minor allele frequency (MAF) greater than 0.007 were excluded
from all analyses.
We performed a hierarchical analysis to identify CpGs linked to interaction of duration of
breastfeeding and maternal smoking during pregnancy and with eczema at age 18 years (Figure
5). We excluded all participants that have eczema at age 10 years to avoid its influence on DNAM at age 10 years and eczema at age 18 years. Thus, we have a clear predictive forward timeorder with exposures (maternal smoking during pregnancy and breastfeeding duration) predicting
DNA-M at age 10 years and DNA-M predicting eczema at age18 years. Since cell types can
influence DNA-M, we have used the residual methylation of all CpGs after regressing the DNAM on cell type proportions throughout in the analyses.
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349555 CpGs
(cell type residuals)
n=276
(i) Association of interaction of
breastfeeding duration and
maternal smoking with DNA-M at
age 10

Linear regression

15034 CpGs

(ii) Association of
DNA-M at age 10 with
eczema at age 18.

Log linear regression
Eczema at age 10

975 CpGs associated at α= 0.05,
7 survive FDR

(iii) Appropriate
directionality of association

4 CpGs

(iv) Confounding assessment between the
associations of :
(i) of interaction of breastfeeding duration
and maternal smoking with DNA-M at age 10
(ii) DNA-M and eczema at age 18

3 CpGs

(v) Inspect and remove outliers in
the distribution of CpGs

3 CpGs

Figure 5 Flow of analyses to identify CpGs at age 10 years associated with longer duration
of breastfeeding if the mother smokes during pregnancy and eczema at age 18 years.

67

The hierarchical steps of analyses are described in detail below (Figure 5):
In step (i) to identify CpGs associated with interaction of maternal smoking and duration
of breastfeeding in eczema free children at age 10 years (n=276) we performed a genome-wide
screening with 349,455 CpGs at age 10 years as outcome and with main effects and their
interaction of gestational smoking and duration of breastfeeding as predictors. We selected the
CpGs at age 10 years that had a statistically significant (α≤0.05) interaction term, i.e., the CpGs
show a significant difference in methylation per week increase of duration of breastfeeding if the
mother smoked during pregnancy compared to if she did not smoke. In the next step (ii), we
tested the selected CpGs for association with eczema at age 18 years using a log-linear model
adjusting for multiple testing (FDR p-value ≤0.05). The CpGs that survive multiple testing
adjustments (false discovery (FDR) p-value ≤0.05) in step (ii) were assessed for appropriate
directionality in step (iii). We selected CpG that show an opposite direction of associations with
interaction of gestational smoking and duration of breastfeeding on the one hand and eczema on
the other hand. In other words, a CpG can be protective under two situations:
(a) CpGs whose methylation at age 10 years is increased with increasing duration of
breastfeeding if the mother smoked during pregnancy, and this higher methylation is associated
with a reduced risk of eczema at age 18 years; or
(b) CpGs whose methylation at age 10 years is reduced with increasing duration of
breastfeeding if the mother smoked during pregnancy, and this lower methylation is associated
with a reduced risk of eczema at age 18 years.
In step (iii) we select the CpGs with direction of associations as (a) or (b) above. The
associations of these selected CpGs were more stringently assessed by adding confounders in
step (iv). Potential variables that may confound the association between interaction of gestational
68

smoking and breastfeeding duration with DNA-M were added in the linear regression models
separately for each of the selected CpGs. Similarly, potential confounders were added in the loglinear regression models assessing the association between DNA-M and eczema at age 18
separately for each CpG. Several genetic and clinical confounders, such as maternal and paternal
history of eczema, birth order of the child, filaggrin (FLG) loss of function genetic variants,
socioeconomic status, and maternal smoking were checked. Confounders that change the
observed effect sizes in regression models by more than 10% were retained in the model. The
CpGs that were still significantly associated after retaining such confounders were then
examined for presence of outliers in their distributions, which could influence the associations
(step (v)) by checking the regression fit plots. The CpGs that remain significantly associated with
the interaction term and the outcome were finally selected.
Additionally, we assessed the DNA-M of the selected CpGs at birth/within a week of
birth (from Guthrie cards, n=724). When the blood is collected on Guthrie cards, the offspring
has been exposed to the smoke in utero and may have had very few days of breastfeeding. We
investigated whether Guthrie DNA-M are associated with gestational smoking and whether
methylation from Guthrie cards can predict eczema at age 18 years prior to breastfeeding effects.
We investigated whether the combined effect of both gestational smoking and duration of
breastfeeding contributes to the variation in the DNA-M at age10 years other than the variation
explained by DNA-M from Guthrie cards. To this end, using methylation data at both time points
in 172 participants we ran a linear regression with DNA-M at age 10 as outcome and the
interaction of gestational smoking and duration of breastfeeding and DNA-M from Guthrie cards
as predictors.
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Gestational smoking and duration of breastfeeding are interdependent variables, because
women who smoke during gestation initiate breastfeeding later [143] and wean earlier [144]. For
this reason, we regressed duration of breastfeeding on gestational smoking and calculated the
residual duration of breastfeeding. Thereafter, we checked whether the interaction of gestational
smoking and residual duration of breastfeeding is associated with the selected CpG sites.

Results
There were no significant differences in the proportion of eczema prevalence, duration of
breastfeeding, gender, maternal smoking during pregnancy, socioeconomic status, filaggrin loss
of function mutation, and maternal and paternal eczema assessed during pregnancy between the
whole cohort (N=1294) and those with DNA-M information at age 10 (n=276) (Table 8). Since
eczema at age 10 years may concurrently influence DNA-M at age 10 years and also be linked to
future eczema at age 18 years, we included only the participants, who were eczema-free at age
10 years (n=276). In the first step (i), 349,555 whole genome CpGs at age 10 years (Figure 5)
were tested in a linear regression model with main effects of maternal smoking and duration of
breastfeeding and their interaction term as predictors. 15,034 CpGs were significantly associated
with the interaction term, which were then tested for association with eczema at age 18 in step
(ii). In this step, we found 975 CpGs to be associated with eczema, of which seven survive
multiple testing. In the next step (iii), we selected protective CpGs showing opposite association
with the risk factors and eczema. Four CpGs fulfilled the above mentioned directionality
conditions (Figure 5). These four CpGs were further assessed with confounders in step (iv)
where gender, socioeconomic status, maternal smoking during pregnancy, and maternal and
paternal eczema were added as potential confounders in linear regression assessing the
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association between interaction of maternal smoking and breastfeeding duration and DNA-M.
For the association of DNA-M and eczema at age 18, all the above confounders and FLG loss of
function and birth order were added in the log-linear model. We retained the confounders that
change the observed effect sizes in regression models by more than 10%. The CpGs that
remained significant after retain such confounders were checked for presence of outliers which
were excluded if present in step (v). On excluding the outliers, one the CpGs was no longer
significantly associated with interaction of maternal smoking and duration of breastfeeding and
was no longer assessed. The three CpGs: cg07208825 (ALMS1P), cg12954512 (Intergenic), and
cg21601919 (FGF18) still remained significantly associated with both interaction of maternal
smoking during pregnancy and duration of breastfeeding and with eczema, respectively (Table 9
and 10).
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Table 8. Comparison of population characteristics between the whole cohort and those with
DNA methylation at age 10 years.
Sample with
Covariates
Whole cohort DNA-M at age
10 years
N =1294
n=276
N (%)
n (%)
p-val
0.25
Maternal smoking during pregnancy
Yes
300 (23.2)
55 (19.9)
No
989 (76.4)
219 (79.3)
Missing
5 (0.39)
2 (0.7)
0.07
Eczema at age 18
Yes
157 (12.1)
23 (8.3)
No
1131 ( 87.4)
253 (91.6)
Missing
6 (0.46)
0.06
Sex
Boys
644 (49.7)
155 (56.2)
Girls
650 (50.2)
121 (43.8)
0.97
Socio economic status
High
102 (7.9)
24 ( 8.7)
Medium
937 (72.4)
209 (75.7)
Low
176 (13.6)
41 (14.8)
Missing
79 (6.1)
2 (0.7)
0.43
Filaggrin loss of function variants
Yes
107 (8.3)
22 (8.0)
No
968 (74.8)
241 (87.3)
Missing
219 (16.9)
13 (4.7)
0.84
Maternal eczema during pregnancy
Yes
160 (12.4)
33 (12.0)
No
1124 (86.9)
241 (87.3)
Missing
10 (0.8)
2 (0.7)
0.31
Paternal eczema during pregnancy
Yes
90 (6.9)
24 (8.7)
No
1186 ( 91.6)
249 (90.2)
Missing
18 (1.4)
3 (1.1)
0.30
Birth Order
1
469 (36.2)
105 (38.04)
2
362 (30)
80 (30)
3
262 (20.2)
71 (25.7)
Missing
201 (15.5)
20 (7.25)
Median (p5, p95)
8.0 (0, 40)
12.0 (0, 40)
0.06
Duration of breastfeeding (weeks)
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Table 9. Association of maternal smoking, duration of breastfeeding and their interaction with methylation at age 10
years (n=276) of cg07208825 (ALMS1P), cg21601919 (FGF18), and cg12954512 (Intergenic). Cell type residuals of
methylation are used in the analyses.
cg07208825
cg21601919
cg12954512
(ALMS1P)
(FGF18)
(Intergenic)
Parameter
Levels
Estimate p-value Estimate p-value Estimate p-value
Maternal smoking during pregnancy
0.031
0.62
-0.117
0.13
-0.16
0.41
Duration of breastfeeding (weeks)
0.001
0.35
-0.002
0.19
-0.001
0.75
Maternal smoking during pregnancy
×
Duration of breastfeeding (weeks)

Overall
0 weeks
4 weeks
12 weeks
24 weeks
36 weeks

-0.007
0.03
0.003
-0.05
-0.13
-0.21
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0.046
0.62
0.95
0.26
0.03
0.02

0.01
-0.11
-0.07
0.007
0.13
0.25

0.02
0.13
0.25
0.9
0.09
0.03

0.022
-0.16
-0.07
0.11
0.38
0.65

0.04
0.4
0.67
0.46
0.05
0.03

Table 10. Association of methylation at age 10 years (n=276) of cg07208825 (ALMS1P),
cg21601919 (FGF18), and cg12954512 (Intergenic) with eczema at age 18. Cell type
residuals of methylation are used in the analyses.
Ilmnid
Levels of
Risk
95% CI
95% CI
p-value
(Gene name)
DNA-M
ratio
(Lower)
(Upper)
14.9
5.5
40.4
1.3E-07
-0.4
0.3
0.23
0.50
9.42E-08
-0.3
0.4
0.33
0.60
9.42E-08
-0.2
0.5
0.48
0.71
9.42E-08
cg07208825
-0.1
0.8
0.69
0.84
9.42E-08
(ALMS1P)
0.1
1.3
1.19
1.45
9.42E-08
0.2
1.7
1.41
2.10
9.42E-08
0.3
2.3
1.68
3.05
9.42E-08
0.4
3
1.99
4.43
9.42E-08
0.20
0.09
0.4
1.56E-06
-0.4
2.0
1.51
2.67
1.52E-06
-0.3
1.7
1.36
2.09
1.52E-06
-0.2
1.4
1.23
1.63
1.52E-06
cg21601919
-0.1
1.2
1.11
1.28
1.52E-06
(FGF18)
0.1
0.8
0.78
0.90
1.52E-06
0.2
0.7
0.61
0.81
1.52E-06
0.3
0.6
0.48
0.73
1.52E-06
0.4
0.5
0.37
0.66
1.52E-06
0.7
0.45
0.86
3.90E-03
-2.0
2.6
1.36
4.91
3.60E-03
-1.5
2.0
1.26
3.30
3.60E-03
-1.0
1.6
1.17
2.22
3.60E-03
cg12954512
-0.5
1.3
1.08
1.49
3.60E-03
(Intergenic)
0.1
1.0
0.92
0.98
3.60E-03
0.5
0.8
0.67
0.93
3.60E-03
1.0
0.6
0.45
0.86
3.60E-03
1.5
0.5
0.30
0.79
3.60E-03

The methylation of cg07208825 (ALMS1P) decreased with increasing duration of
breastfeeding if the mother smoked during gestation (Estimate: -0.006, p-value: 0.046 for
cg07208825 (ALMS1P)). In turn, higher methylation of this CpG was associated with increased
risk of eczema at age 18 years (parameter estimate: 14.23, p-value: 1.27E-07 for cg07208825
(ALMS1P)) (Tables 9 and 10, Figure 6).
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(i)

(A)

(ii)

Figure 6. Association of cell type residuals of DNA-M with interaction of maternal smoking and breastfeeding duration, and with
eczema at age 18 years (A) cg07208825 (ALMS1P) (B) cg21601919 (FGF18) (C) cg12954512 (Intergenic). The panels are described
as follows: (i) Association of DNA-M at age 10 years with duration of breastfeeding; (ii) Association of DNA-M at age 10 years with
eczema at age 18 years in participants with maternal smoke exposure during pregnancy.
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(iii)

(iv)
(B)

Figure 6 (continued): Association of cell type residuals of DNA-M with interaction of maternal smoking and breastfeeding duration,
and with eczema at age 18 years (A) cg07208825 (ALMS1P) (B) cg21601919 (FGF18) (C) cg12954512 (Intergenic).
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(C)

(v)

(vi)

Figure 6 (continued): Association of cell type residuals of DNA-M with interaction of maternal smoking and breastfeeding duration,
and with eczema at age 18 years (A) cg07208825 (ALMS1P) (B) cg21601919 (FGF18) (C) cg12954512 (Intergenic).
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For the other two CpGs, the methylation of cg12954512 (Intergenic) and cg21601919
(FGF18) increased with increasing duration of breastfeeding if the mother smoked during
gestation (Estimate: 0.021, p-value: 0.036 for cg12954512 (Intergenic) and parameter estimate:
0.008, p-value: 0.016 for cg21601919 (FGF18)). In turn, higher methylation of these CpGs was
associated with lower risk of eczema at age 18 years (Risk ratio: 0.62, p-value: 3.90E-03 for
cg12954512 (Intergenic) and Risk ratio: 0.18, p-value: 1.56E-06 for cg21601919 (FGF18))
(Table 9 and 4.3, Figure 6).

The CpG cg07208825 (ALMS1P) is located on chromosome 2 on the 200 bp upstream
from transcription start site (promoter region), cg21601919 (FGF18) is located in the body
region of chromosome 5 whereas the CpG cg12954512 is located on chromosome 7 between the
genes WDR60 and LINC00689.

Then it was determined whether exposure to gestational smoking alone affected the
DNA-M collected from Guthrie cards (prior to establishing a breastfeeding effect) such that they
predict a lower risk of eczema at age 18 years. DNA-M of the selected CpGs measured in
Guthrie cards (n=724) were not associated with maternal smoking during pregnancy, and did not
predict eczema at age 18 years (Data not shown). This shows that these CpGs at birth were not
differentially methylated by gestational smoking alone, and could not explain future eczema at
age 18 years, without the influence of breastfeeding.

Next, DNA-M at birth (from Guthrie cards) and DNA-M at age 10 years in participants
with methylation information at both time points (n=172) were compared. Linear regression
were used for each of the three selected CpGs with DNA-M at age 10 as outcome and the
interaction of gestational smoking and duration of breastfeeding and controlling for DNA-M
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from Guthrie cards as predictors. For the CpG cg21601919 (FGF18), DNA-M at birth was not
associated with DNA-M at age 10 years. However, interaction of gestational smoking and
duration of breastfeeding remained significantly associated with DNA-M at age 10 years
(Estimate: 0.01, p-value: 0.045) indicating that their combined effect explains the variation in
DNA-M at age 10 years that is not explained by DNA-M at birth (or within a week of birth) of
cg21601919 (FGF18). Additionally, the direction of association is still the same as we found in
our screening step with DNA-M at age 10 years. In other words, longer duration of breastfeeding
is associated with an increase in the DNA-M at age 10 years if the mother smoked during
pregnancy even after adjusting for DNA-M at birth/within a week of birth of cg21601919
(FGF18).

Although for the other two CpGs the interaction term was no longer significant after
adjusting for DNA-M at birth/within a week of birth, the direction of the interaction was still in
agreement as we found at age 10 years (parameter estimate: -.006, p-value: 0.13 for cg07208825
(ALMS1P); parameter estimate: 0.019, p-value: 0.3 for cg12954512 (Intergenic)) (Table 11).
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Table 11. Association of maternal smoking during pregnancy and duration of breastfeeding with DNA-M at
age 10 (post breastfeeding) adjusted for DNA-M from Guthrie cards (collected at birth or within a week of
birth)
Ilmnid
Parameter
Levels
Estimate
p-value
DNAM from Guthrie cards
0.31
0.0003
Maternal smoking during pregnancy
Yes
0.08
0.23
cg07208825
No (Ref.)
(ALMS1P)
Duration of breastfeeding (weeks)
0.0012
0.45
Maternal smoking during pregnancy ×
-0.007
0.13
Duration of breastfeeding (weeks)
DNAM from Guthrie cards
-0.11
0.14
Maternal smoking during pregnancy
Yes
-0.13
0.13
No (Ref.)
cg21601919
(FGF18)
Duration of breastfeeding (weeks)
-0.002
0.26
Maternal smoking during pregnancy ×
0.011
0.045
Duration of breastfeeding (weeks)
DNAM from Guthrie cards
0.39
<.0001
Maternal smoking during pregnancy
Yes
-0.68
0.02
No (Ref.)
cg12954512
(Intergenic)
Duration of breastfeeding (weeks)
-0.0005
0.93
Maternal smoking during pregnancy ×
0.02
0.3
Duration of breastfeeding (weeks)
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The pattern of DNA-M in participants with methylation information at both time points
(n=172) is shown in Figure 7. The development of the mean DNA-M in participants of different
breastfeeding groups (not breastfed, breastfed for <=3 months, and breastfed for >3 months)
were plotted from birth to age 10 years, comparing children with and without maternal smoke
exposure during gestation. Figure 7 (a) shows that if mothers smoked during gestation (left
graph) the methylation of cg07208825 (ALMS1P) is lower at age 10 years compared to that at
birth in those who breastfeed for > 3 months and lower DNA-M of this CpG is protective for
eczema (Table 10, Figure 6a). However, if the mothers did not smoke during gestation (right
graph), the DNA-M is higher at age 10 years than at birth in those who breastfeed for > 3
months. Similarly, the methylation of cg21601919 (FGF18) and cg12954512 (Intergenic) also
show contrasting patterns for longer periods of breastfeeding if the mother smoked during
gestation vs. if she did not.

Regarding the two exposures variables, gestational smoking is known to reduce duration
of breastfeeding and even delay the initiation of breastfeeding [143, 144]. Hence, duration of
breastfeeding may be affected by gestational smoking and thus cannot be an independent risk
factor used in the interaction term of gestational smoking and breastfeeding duration. We
considered this by ‘extracting’ the part of the duration of breastfeeding that is due to gestational
smoking. To this end duration of breastfeeding was regressed on gestational smoking and the
residual duration of breastfeeding were calculated. Taking the interaction of gestational smoking
and residual duration of breastfeeding into account, the associations were was still significantly
associated in the same direction and similar effect sizes with DNA-M at age 10 years of all three
selected CpGs (Table 12).
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(A)

(B)
Figure 7. Pattern of DNA-M from Guthrie cards and age 10 years in participants who did not breastfeed, breastfeed for less than three
months, and more than three months between smokers and non-smokers (A) cg07208825 (ALMS1P) (B) cg21601919 (FGF18) (C)
cg12954512 (Intergenic).
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(C)

Figure 7 (Continued). Pattern of DNA-M from Guthrie cards and age 10 years in participants who did not breastfeed, breastfeed for
less than three months, and more than three months between smokers and non-smokers (A) cg07208825 (ALMS1P) (B) cg21601919
(FGF18) (C) cg12954512 (Intergenic).
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Table 12. Association of gestational smoking and residual duration of breastfeeding with DNA-M at age
10 (n=276). The residual duration of breastfeeding is calculated by regressing the duration of
breastfeeding on gestational smoking.
Ilmnid
Parameter
Levels
Estimate
p-value
Maternal smoking during pregnancy
Yes
-0.05
0.26
No (Ref.)
cg07208825
Duration of breastfeeding (weeks)
0.0012
0.4
(ALMS1P)
Maternal smoking during pregnancy
×
Yes
-0.006
0.045
Duration of breastfeeding (weeks)
Maternal smoking during pregnancy
Yes
0.007
0.9
No (Ref.)
cg21601919
Duration of breastfeeding (weeks)
-0.022
0.2
(FGF18)
Maternal smoking during pregnancy
×
Yes
0.01
0.02
Duration of breastfeeding (weeks)
Maternal smoking during pregnancy
Yes
-0.13
0.5
No (Ref.)
cg12954512
Duration of breastfeeding (weeks)
-0.001
0.8
(Intergenic)
Maternal smoking during pregnancy
×
Yes
0.03
0.03
Duration of breastfeeding (weeks)
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Discussion

Our results suggest that combined effects of gestational smoking and duration of
breastfeeding influence the DNA-M at age 10 years of cg07208825 (ALMS1P), cg12954512
(Intergenic), and cg21601919 (FGF18), which in turn predict a lower risk of eczema at age 18
years.

To identify CpGs at age 10 years, which methylation are linked to duration of
breastfeeding and maternal smoking during pregnancy and with eczema at age 18 (n=276), we
performed a hierarchical screening. We excluded any participants who had eczema at age 10
years to avoid reverse causation of eczema at age 10 years influencing DNA-M at age 10 years
and its association with eczema at age 18 years.

We first checked the association of interaction of maternal smoking during pregnancy
and duration of breastfeeding with DNA-M of genome wide CpGs at age 10 years. The CpGs
significantly associated with the interaction term were tested for association with eczema at age
18 years and corrected for multiple testing using FDR. The CpGs which survived multiple
testing were assessed further for appropriate directionality. For instance, we focused on CpGs
whose methylation at age 10 years increase with increasing duration of breastfeeding if the
mother smoked during pregnancy, and higher methylation was associated with a reduced risk of
eczema at age 18 years, or vice versa. We assessed the associations for confounding and
removed any outliers in the methylation that could influence the regressions. Finally, the three
CpGs: cg07208825 (ALMS1P), cg12954512 (Intergenic), and cg21601919 (FGF18) still
remained significantly associated with both interaction of maternal smoking during pregnancy
and duration of breastfeeding and with eczema, respectively (Table 9 and 10).
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Additionally, the selected CpGs measured at birth/within a week of birth from Guthrie
cards (n=724) were not associated with gestational smoking, and did not predict eczema at age
18 years (data not shown). This suggests that gestational smoking alone is not sufficient to bring
about a change in methylation, and methylation at this time point, not yet influenced by
breastfeeding, could not explain eczema at age 18 years.
There are several limitations of this study. Firstly, we used a nominal p-value (α<=0.05)
to select CpGs at age 10 years associated with interaction of gestational smoking and duration of
breastfeeding without adjusting for multiple testing. Although there is a possibility of identifying
false positives CpGs, the purpose of this step was to screen for informative CpGs linked to
gestational smoking and duration of breastfeeding to reduce number of variables to be tested for
association with eczema. However, in the next step we corrected for multiple testing and select
only those CpGs which have an FDR p-value <=0.05 for the association between DNA-M at age
10 years and eczema at age 18 years. Further filtering of the CpGs took place in the next step
based on the criteria of directionality, confounding, and outliers so that starting with the 349455
CpGs only four are finally selected.

Secondly, the effect size of association of combined effect of gestational smoking and
duration of breastfeeding and eczema is small. However, we investigated this small effect size by
comparing the DNA-M at birth/ within a week of birth from Guthrie cards (collected post
exposure to gestational smoking but prior to breastfeeding) with that at age 10 years (collected
post gestational smoking and breastfeeding) in a sample of participants with methylation at both
time points (n=172). We investigated whether interaction of maternal smoking and duration of
breastfeeding can explain the variation in the DNA-M at age 10 years after adjusting for DNA-M
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measured at birth/within a week of birth from Guthrie cards. We found that the interaction term
was significantly associated with DNA-M at age 10 years for cg21601919 (FGF18) whereas
DNA-M from Guthrie cards was not significantly associated with DNA-M at age 10 years
(Estimate: -0.11, p-value: 0.14). The DNA-M from Guthrie cards explained the variation in
DNA-M at age 10 years for cg07208825 (ALMS1P) (parameter estimate: 0.31, p-value: 0.0003)
and cg12954512 (Intergenic) (Parameter estimate: 0.39, p-value: <0.0001. Although the p-value
of the association of interaction term with DNA-M at age 10 is only marginally significant for
cg07208825 (ALMS1P) and non-significant cg12954512 (Intergenic), the direction of the effect
of longer duration of breastfeeding if the mother smokes during pregnancy is predictive of lower
risk of eczema at age 18 for all three CpGs (Table 11). These findings indicate that the combined
effect of gestational smoking and duration of breastfeeding is required influence the DNA-M at
age 10 years.

We could not take into account passive smoke exposure after birth, which remains a
limitation. However, none of the participants started smoking cigarettes themselves at age 10
years when the DNA-M information was assessed. Additionally, none of the selected CpGs were
associated with current smoking at age 18 years, indicating no confounding of the association
between DNA-M and eczema at age 18 years.

We additionally examined the pattern of eczema at age 1 and 2, 4, 10 and 18 in the
sample analyzed with DNA-M at age 10 years (n=276, eczema free at age 10 years). There were
six participants who had eczema in either age 1-2 or age 4 or both, with remission at age 10 and
re-occurrence at age 18 years. It is possible that these participants were misclassified to be
eczema free at age 10 years or that these children still carry a non-identifiable risk. To avoid any
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such misclassification of eczema at age 10 years, in a side-analysis we excluded these six
participants. Nevertheless, the associations of CpGs with interaction of maternal smoking and
breastfeeding duration and with eczema at age 18 years remained statistically significant.

One of the limitations of this study is that the maternal smoking status is self-reported.
However, we have assessed the DNA methylation of AHRR, a CpG (cytosine-phosphateguanine) site, cg05575921, of the AHRR gene, a well-established epigenetic biomarker of
smoking. The offspring whose mothers smoked during pregnancy have significantly lower
methylation of this CpG site from Guthrie cards (n=724, parameter estimate: -0.66 and p-value
<0.0001), which is in agreement with the prior studies of prenatal smoke exposure and supports
the validity of the smoking information [48].
Regarding DNA-M , a major measurement error is unlikely since the Illumina Infinium
HumanMethylation850 beadchip array, is known to be high reliable and high reproducible [107].
Since information regarding duration of breastfeeding was collected at year one and two, it can
be considered reliable reducing minimizing the recall bias [77]. Information regarding eczema
was acquired from detailed questions during clinical visits. Eczema was defined as ‘ever eczema’
and having had an ‘itchy rash during the previous 12 months’ and was defined following the
Hanifin and Rajka criteria [69]. The chances of misclassification is minor since the participants
developed rashes developed on typical locations (anticubital or popliteal fossae, ankles, face or
neck) [76].

The major strength of this study is the forward time-order with maternal smoking and
breastfeeding predicting DNA-M at age 10 years of cg07208825 (ALMS1P), cg12954512
(Intergenic), and cg21601919 (FGF18), which in turn predict a lower risk of eczema 18 years.
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Although a link between maternal smoking during pregnancy and DNA-M has been investigated
in various studies [47, 49, 50, 142], there are very few studies on breastfeeding duration and
DNA-M in offspring [51]. Associations of eczema and DNA-M of FLG [110], TSLP and
FCER1G [111], and PROZ and NEU1 [112] has been reported. However, in most of these
studies DNA-M was measured concurrently with the eczema, making it difficult to distinguish
on whether DNA-M results as cause or consequence of the disease-status. No other study has yet
investigated the combined effect of breastfeeding duration and gestational smoking on DNA-M,
and whether the altered DNA-M can predict eczema.

The genes of the above-identified CpGs are functionally relevant with regard to
epidermal differentiation. The CpG cg21601919 is located in the body region of the gene FGF18
(Fibroblast Growth Factor 18). Although the role of methylation in the body region its role is
not completely understood [114], it is known to modify transcriptional efficiency [44]. FGF18 is
expressed in adipose tissue, neurons, and epidermal keratinocytes [145, 146] and is a
downstream target for Wnt/β-catenin signaling pathway crucial for hair and skin development
[147]. In mice, FGF18 was reported to be highly expressed in hair follicles, which are intricately
innervated [148] and mediate neuroimmunoendocrine communication [149]. FGF18 remodels
the hair follicles in telogen (resting) stage to anagen (hair growth) stage [145]. Interestingly,
anagen phase is accompanied with improved wound healing and increased keratinocyte
proliferation [150]. During remodeling of hair follicle both sensory and adrenergic skin
innervation and in mast cell–nerve count undergoes several changes [151, 152]. Interestingly,
interactions between mast cells, nerves and neuropeptides are implicated in atopic dermatitis
[153]. Mast cell derived histamine reportedly induces expression of FGF18 in normal human
dermal fibroblasts [154]. With regard to smoke exposure, methylation of another FGF18 CpG
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site cg16654732 located within 200bp of the TSS s reportedly negatively associated with higher
smoking (pack years) in Italian lung adenocarcinoma (LUAD) cases compared to normal lung
tissue [155]. Additionally, both FGF18 and AHR (an intracellular receptor for dioxins in
cigarette smoke) were reported to be differentially expressed in neuroblastoma tumors and were
enriched in the same functional category of cell proliferation and differentiation [156].

The CpG cg12954512 is located on chromosome 7 between the genes WDR60 and
LINC00689. Interestingly, the protein WDR60 is a dynein intermediary chain that is essential for
the assembly of cilia [157, 158]. Cilia sense external stimuli and direct these signals influencing
cell fate decisions such as growth or differentiation [159]. Interestingly, experimental ablation of
cilia in the dermal cells causes an arrest of hair follicle development [160], whereas cilia in the
epidermal cells are involved in in epidermal stress responses, and normal keratinocyte
differentiation [161]. Additionally, cutaneous nerve fibers are present surrounding keratinocytes
and cilia [162], which also plays a role in maintaining interneuronal connectivity [163].
LINC00689 is a long non-coding RNAs (lncRNAs) produce transcripts over 200 nucleotides in
length, which do not translate in to proteins [132]. lncRNAs are found encapsulated in
extracellular vesicles of breastmilk [132] play a role in regulation of gene expression [133] and
are linked to actinic dermatosis [134] and psoriasis [135].

The CpG cg07208825 belongs to promoter region (TSS200) of ALMS1P, a pseudo gene
situated next to its parental gene ALMS1 (Centrosome and Basal Body Associated Protein) on
chromosome 2. Lower methylation of pseudogenes promoters are linked to higher expression of
parental gene expression [164, 165]. We find that the methylation of cg07208825 (ALMS1P) is
lower with longer duration of breastfeeding if the mother smokes during pregnancy, which
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indicates a possibility of higher expression of the parental gene ALMS1. Interestingly, ALMS1
plays a role assembly and function of cilia [116] and interacts with actin cytoskeleton proteins
important for cell-to-cell adhesion [116].

Although peripheral blood methylation of the detected genes is relevant with respect to
eczema, it remains an open question whether peripheral blood methylation can be used as a
substitute for tissue specific genes. Interestingly, these genes are expressed not only skin, but
also several other tissues including in whole blood (www.genecards.com). Additionally, several
studies have found similar methylation of specific genes in blood and other organs [136, 137],
reinforcing that whole blood methylation can reflect the methylation pattern of specific tissues.
It is known that gestational smoking may lead the mothers to initiate breastfeeding later
[143] and stop breastfeeding earlier [144]. Although these two variables are interdependent, we
calculated the residual duration of breastfeeding by regressing the duration of breastfeeding on
gestational smoking. We find interaction of gestational smoking and residual duration of
breastfeeding was still associated with DNA-M at age 10 years of all three selected CpGs (Table
12) in the same direction. This implies that part of duration of breastfeeding that is not explained
by gestational smoking is still associated with DNA-M at age 10 years and this association varies
between children with mothers who smoked during pregnancy compared to children with nonsmoking mothers.

This is the first study investigating interplay of maternal smoking and duration of
breastfeeding on DNA methylation of genes which related to eczema. Our results suggest that
longer duration of breastfeeding combined with gestational smoking is associated with
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methylation of genes related to hair follicle and cilia formation, which in turn are linked with
lower risk of eczema.

Topical application of tobacco leaves and coal tar that has polycyclic aromatic
hydrocarbons (PAHs) similar to tobacco smoke, have been used as ancient remedies of eczema
[32, 166, 167]. Although nicotine and other substances from tobacco smoke may pass through
placenta and reach the developing offspring[168], we do not find gestational smoking to be
associated with DNA-M of these selected CpGs at birth (within a week of birth) indicating inutero exposure is not sufficient to induce a change in DNA-M.

Our results show a combined effect of both gestational smoking and breastfeeding
duration, with increasing duration affecting the DNA-M, and DNA-M in turn linked to a lower
risk of eczema. Nicotine, however, is also stored in the fat particles in the breasts and high
amounts and is detected in breastmilk if the mother smokes during breastfeeding [30, 31].
Interestingly, nicotine suppresses inflammation in obese mice through cholinergic antiinflammatory pathway acting via the α7-nicotinic acetylcholine receptors (α7nAChR) [36].
These receptors are also present epidermal hair follicles and dermal fibroblasts in mice and scalp
epidermis in humans [169]. Not only nicotine, in smoking mothers several hormones and
cytokines such as IL-1α are also altered in breast milk of smoking women [37]. Thus, future
research is warranted regarding how breastmilk composition in those who smoked during
pregnancy impacts DNA-M in the offspring. Our results suggest that in particular mothers who
do not quit smoking during pregnancy should still be encouraged to breastfeed their children.
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CHAPTER 5
CONCLUSION
In this dissertation I have investigated the interplay of gestational smoking and duration
of breastfeeding on eczema in offspring. In Specific Aim 1 (SA1), my hypothesis is that
gestational smoking and duration of breastfeeding jointly influence the risk of eczema. I
analyzed the repeated measurements of eczema at ages 1-2 years, 4, 10, and 18 years as outcome
using the generalized estimating equation (GEE) approach. I obtained a significant interaction
term of gestational smoking and duration of exclusive breastfeeding and the combined effect
estimated as follows: RR= exp (β1×maternal smoking + β2×duration of exclusive breastfeeding
+β3× (maternal smoking× duration of exclusive breastfeeding)). I assessed confounding using the
10% rule. I found longer duration of breastfeeding (weeks) to be associated with a lower risk of
eczema if the mother smoked during pregnancy. The risk ratios for eczema related to maternal
smoking and their 95% CI for 3, 9, 15, 21 weeks of breastfeeding were 0.88 (0.66, 1.20), 0.74
(0.54, 1.01), 0.62 (0.41, 0.93), and 0.51 (0.3, 0.88), respectively. Upon stratification, only when
the mother smoked during gestation, there is a protective effect of longer duration of
breastfeeding on eczema. Using configural frequency analysis (CFA), I found that persistent
eczema was statistically significantly more frequent across all the time points of 1-2 years, 4, 10,
and 18 years. Additionally the risk of persistent eczema is lower compared to no eczema with
longer duration of exclusive breastfeeding if the mother smoked during pregnancy.

Specific Aim 2 (SA2) was to explore whether duration of breastfeeding is linked to DNA
methylation (DNA-M) which in turn explain a differential risk of eczema at age 18 years. My
hypothesis is that longer duration of breastfeeding may alter methylation of CpGs such that they
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are associated with lower risk of eczema at age 18 years. To have an appropriate time order, I
investigated the effect of breastfeeding duration on DNA-M at age 10 years and eczema at age
18 years. I included in analysis only children who were eczema-free at age 10 years. I first
identified informative CpGs with associated with duration of breastfeeding using linear
regression (α<=0.05), followed by testing the association of these CpGs with eczema at age 18
years adjusting for FDR. Only those informative CpGs that were also associated with eczema at
age 18 years at a false discovery rate adjusted p-value <=0.05 were further investigated. Since I
am interested in protective effects of breastfeeding duration on eczema, I selected the CpGs that
show opposite associations i.e., CpGs which are:
(i)

whose methylation at age 10 years increase with longer duration of breastfeeding, and
higher methylation was associated with a reduced risk of eczema at age 18 years; or

(ii)

whose methylation at age 10 years reduce with longer duration of breastfeeding, and
lower methylation was associated with a reduced risk of eczema at age 18 years.
In the next step, I assessed confounding for both the associations (breastfeeding and

DNA-M, and DNA-M with eczema at age 18 years), followed by path analyses to assess whether
there is any indirect effect via these CpGs. Four CpGs passed the applications of these criterial In
the path analyses, The methylation of each of the four CpGs, namely, cg03605610 (between
NRC2 and LINC01276), cg04928096 (AXIN1), cg26375057 (ZIC1) and cg26979504 (HHEX) at
age 10 years was in the causal pathway between duration of breastfeeding reducing the risk of
eczema at age 18 years (Figure 4). The genes of the detected methylation sites are associated
with fatty acids, cell–cell adhesion, apoptosis, and retinoic acid signaling pathway and provide
an insight regarding their role in eczema pathogenesis linked to breastfeeding exposure.
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In Specific Aim 3 (SA3), I assessed the effect of gestational smoking, breastfeeding
duration, and DNA-M on eczema. The protective combined effect of gestational smoking and
breastfeeding duration that I found in Specific Aim 1 directed me to investigate whether DNA-M
can explain this protective effect. My hypothesis is that the combined effect of gestational
smoking and breastfeeding duration is associated with DNA-M of CpG sites that can explain a
lower risk of eczema at age18 years. The same time order as SA2 was applied, starting with
DNA-methylation of eczema-free children. Then it was tested, whether the interaction of
gestational smoking and breastfeeding duration predicts DNA-M at age 10 years and the DNAM at age 10 years predicts eczema at age 18 years. I first identify informative CpGs associated
with interaction of gestational smoking and duration of breastfeeding using linear regression
(α<=0.05), and testing these informative CpGs with eczema at age 18 years using log-linear
regression followed by FDR adjustment. Among these CpGs I focused on the following DNA-M
markers:
a) CpGs whose methylation at age 10 years is increased with increasing duration of breastfeeding
if the mother smoked during pregnancy, and this higher methylation is associated with a reduced
risk of eczema at age 18 years; or
(b) CpGs whose methylation at age 10 years is reduced with increasing duration of breastfeeding
if the mother smoked during pregnancy, and this lower methylation is associated with a reduced
risk of eczema at age 18 years.
In the next step I assessed confounding for both the associations (interaction of
breastfeeding duration and gestational smoking on DNA-M, and DNA-M with eczema at age 18
years).
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I identified three CpG [cg07208825 (ALMS1P), cg12954512 (Intergenic), and
cg21601919 (FGF18)] which remained significantly associated with duration of breastfeeding
and gestational smoking, and with eczema at age 18 years after including relevant confounders
(Figure 6). These CpGs are linked to hair follicle and cilia formation are play a role in
keratinocyte differentiation.

Limitations and strengths:
1. Interdependence of exposures: Although it is known that gestational smoking may negatively
affect breastfeeding initiation, and even lead to early weaning [143, 144]., in SA1 I find a lower
risk of eczema in those participants who were exposed to gestational smoking and were breastfed
for a longer period of time. This association remained statistically significant even after adjusting
for relevant confounders. Additionally, we regressed duration of exclusive breastfeeding on
maternal smoking during pregnancy and calculated the residual duration of exclusive
breastfeeding. The interaction of residual exclusive breastfeeding duration and gestational
smoking showed a similar significant protective effect on eczema with longer duration of
breastfeeding.
2. Analytical strategy: In SA1 we model the repeated measurements of eczema status repeatedly
measured at age 1-or-2 (year 1 and 2 combined), 4, 10, and 18 year using the generalized
estimating equation (GEE) approach with the interaction of the exposures: gestational smoking
and duration of breastfeeding as predictors along with relevant confounders.
Although in this setting, in children the development of eczema may have been initiated at age 12 years, at the same time when they were being breastfed. This indicates that there remains a
possibility of reverse causation at this time point. However, we took this into account in SA2 and
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SA3, in which a clear predictive time order was applied with duration of breastfeeding and
gestational smoking predicting DNA-M at age 10 years and DNA-M at age 10 years predicting
eczema at age 18 years. Additionally, we included only those participants who are eczema-free at
age 10 years to assure that there is no influence of eczema at age 10 years on DNA-M at age 10
years.
Since cell types are known to influence DNA-M, I have used cell type residuals of DNAM throughout the analyses of SA2 and SA3.
I performed a linear regression and tested the association of 349455 CpGs at age 10 years
with breastfeeding duration (SA2) and the interaction of gestational smoking and duration of
breastfeeding (SA3) using a nominal p-value (α<=0.05) without adjusting for multiple testing.
Although this indicates a possibility of having false positives, in this first step I wanted to screen
for informative CpGs so that I have a reduced number of variables to be tested for association
with eczema. I performed a log linear regression to test the association of the selected
informative CpGs with eczema at age 18 years and then adjust for FDR. Among the CpGs that
survive FDR, I finally select the ones that follow the directionality criteria of opposite
associations with exposures and eczema at age 18.
3. Small effect sizes In SA1, although the overall effect size of the interaction term of gestational
smoking and duration of breastfeeding was small, it was clearly reduced the risk of eczema at
longer duration of breastfeeding showing that a more pronounced effect is seen at longer
durations.
In SA2 and SA3, the effect size of the associations of duration of breastfeeding (SA2)
and its combined effect of gestational smoking (SA3) had a small effect on DNA-M at age 10
years. To additionally test, whether these small effects indeed show changes of DNA-M related
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to breastfeeding, I compared DNA-M at birth measured in Guthrie cards and compared it with
DNA-M at age10 years in a small sample (n=172). I demonstrated that breastfeeding duration
(SA2)/ interaction of gestational smoking and duration of breastfeeding (SA3) can explain the
variation in the DNA-M at age 10 years after adjusting for DNA-M from Guthrie cards
indicating that they have an effect on DNA-M at age10 years.
4. The peripheral blood methylation of the CpGs that we detected are in SA2 and SA3 are
relevant with respect to eczema. Although an open question remains on whether peripheral blood
methylation can be used as a proxy for tissue specific genes. To this end, I checked the
expression of these genes in an online data base (www.genecards.com) where I found these
genes to be expressed not only skin, but several other tissues including whole blood.
Additionally, several studies have found similar methylation of specific genes in blood and other
organs [136, 137], reinforcing that whole blood methylation can reflect the methylation pattern
of specific tissues.
In conclusion, this dissertation aids in the understanding of effect of two early life
exposures, duration of breastfeeding and maternal gestational smoking with offspring eczema
and the role of DNA methylation as an intermediate factor between these exposures and the
outcome. The current studies linking maternal gestational smoking with offspring eczema have
demonstrated contradictory associations. Similarly, studies linking duration of breastfeeding with
eczema have also yielded conflicting results. Chapter one of this dissertation is the first study to
demonstrate that a combined effect of duration of breastfeeding and maternal smoking is
protective of persistent eczema in the offspring at ages 1-2, 4, 10, and 18 years, which offers a
potential explanation regarding the conflicting results in the literature.
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Whereas chapter one provides and epidemiological association between duration of
breastfeeding, maternal smoking and eczema, chapters two and three provide an insight
regarding how these exposures biologically mediate their effect via altered DNA methylation on
offspring eczema. No existing study has investigated whether differentially methylated sites
associated breastfeeding duration, or with the combined effect of breastfeeding, duration and
maternal gestational smoking can explain the risk of eczema. Chapters two and three focusses on
identification of such differentially methylated sites at age 10 years that may impart a different
risk of eczema at age 18 years in the offspring. The second chapter demonstrates that longer
duration of breastfeeding alone also mediate a protective effect on eczema at age18 years via
DNA-M, whereas the third chapter shows that duration of breastfeeding and gestational smoking
may jointly influence DNA-M that in turn explain a lower risk of eczema at age18 years. To
have an appropriate predictive time order, SA2 and SA3 focus on eczema at age 18 years, where
a delayed effect of the exposures are shown on eczema at age 18 years. These same CpGs may
not be able to explain a protective effect at earlier ages since incident eczema at age 18 may have
a different pathogenesis than that at earlier ages. Replication of these results would be useful to
validate the findings, especially with methylation of the target skin tissue of eczema.
The work detected CpGs belonging to seven new genes whose DNA methylation seems to be
involved in the development of eczema at age 18 years which are described as follows:

I.

The CpG cg04928096 is located on the 3’UTR of the AXIN1 gene. AXIN1 (Axis
Inhibition Protein 1) gene is a part of the Wnt signaling pathway and induces the
ubiquination and degradation of cytosolic β-catenin [170]. β-catenin is involved in cell–
cell adhesion by interacting with cadherin proteins and its degradation may lead to
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apoptosis of cells [117]. Ablation of β-catenin in epidermis has been reported to lead to
barrier dysfunction indicating its role in epidermal function [118], thus corroborating our
findings of higher methylation for the CpG of AXIN1 associated with lower risk of
eczema. No direct association is reported in the literature regarding breastfeeding
duration and the AXIN1 gene. However, it is known that Epidermal Growth Factor
(EGF), a ligand of Epidermal Growth Factor Receptor is abundant in breastmilk [119].
Studies have demonstrated that ligand activated EGFR leads to phosphorylation of
several downstream proteins leading to transfer of Axin complexed with other proteins
(GSK3-APC-Axin complex)[120] to the cell membrane, thus promoting the stabilization
of β-catenin[120]. EGF in breastmilk may also inactivate GSK3 (glycogen synthase
kinase 3) and stabilize β-catenin [119].
II.

The CpG cg26979504 is in the body region of the gene HHEX (Hematopoietically
Expressed Homeobox). This gene codes for a transcription factor that is involved in
several developmental and differentiation processes including that of the mammary
epithelial cells [121]. Puppin et al have reported that higher nuclear localization of HHEX
in lactating tissue compared to normal non-lactating human breast tissue [121].
Kothapalli et al found a higher expression of HHEX in the cerebral cortex region of
baboons who were fed higher amounts of Docosahexaenoic acid (DHA) than controls
[122] indicating a possible link between fatty acids found in breast milk with HHEX
expression. Additionally, lower expression of HHEX was reported in dermal
mesenchymal stem cells in psoriatic skin lesions compared to controls [123] implying its
role in inflammatory skin disease.
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III.

The CpG cg26375057 is located in the first exon of the ZIC1 gene. The ZIC1 (zinc finger
in the cerebellum 1) gene produces a transcriptional activator and is involved in
neurogenesis [124], and is a classic marker of brown adipose tissue (BAT) [125] which is
present in breast tissue [126]. An in-vitro analysis with mice adipose cells reported that
DHA synthesis takes place in the BAT cells [125]. Zic1 is important for maintaining the
expression of retinoic acid (RA)-degrading enzyme cyp26a1 in the forebrain of zebrafish,
with Zic1 loss of function linked to higher the levels of RA [127]. Interestingly, RAs play
a crucial role in the maintenance of epithelial tissues and retinoic acid isomers are also
used as drugs to treat several dermatological diseases [128] including eczema [129].

IV.

The CpG cg03605610 is an intergenic CpG on chromosome 6 lying between the genes
NRC2 (NK Cell-Activating Receptor) and Long Intergenic Non-Protein Coding RNA
1276. NRC2, also known NKp44 is an NK cell activating receptor [130] is implicated in
psoriatic inflammation [131]. Lesional skin and peripheral blood of psoriasis patients
have a high proportion of innate lymphoid cells expressing this receptor (NKp44 ++
ILC3) which also produce the IL22, a cytokine that triggers epidermal thickening in
psoriatic skin [131]. Long non-coding RNAs (lncRNAs) produce transcripts over 200
nucleotides in length, which do not translate in to proteins [132]. They are found
encapsulated in extracellular vesicles of breastmilk [132] playing a role in the regulation
of gene expression [133] and are linked to actinic dermatosis [134] and psoriasis [135].

V.

The CpG cg21601919 is located in the body region of the gene FGF18 (Fibroblast
Growth Factor 18). Although the role of methylation in the body region its role is not
completely understood [114], it is known to modify transcriptional efficiency [44].
FGF18 is expressed in adipose tissue, neurons, and epidermal keratinocytes [145, 146]

101

and is a downstream target for Wnt/β-catenin signaling pathway crucial for hair and skin
development [147]. In mice, FGF18 was reported to be highly expressed in hair follicles,
which are intricately innervated [148] and mediate neuroimmunoendocrine
communication [149]. FGF18 remodels the hair follicles in telogen (resting) stage to
anagen (hair growth) stage [145]. Interestingly, anagen phase is accompanied with
improved wound healing and increased keratinocyte proliferation [150]. During
remodeling of hair follicle both sensory and adrenergic skin innervation and in mast cell–
nerve count undergoes several changes [151, 152]. Interestingly, interactions between
mast cells, nerves and neuropeptides are implicated in atopic dermatitis [153]. Mast cell
derived histamine reportedly induces expression of FGF18 in normal human dermal
fibroblasts [154]. With regard to smoke exposure, methylation of another FGF18 CpG
site cg16654732 located within 200bp of the TSS s reportedly negatively associated with
higher smoking (pack years) in Italian lung adenocarcinoma (LUAD) cases compared to
normal lung tissue [155]. Additionally, both FGF18 and AHR (an intracellular receptor
for dioxins in cigarette smoke) were reported to be differentially expressed in
neuroblastoma tumors and were enriched in the same functional category of cell
proliferation and differentiation [156].
VI.

The CpG cg12954512 is located on chromosome 7 between the genes WDR60 and
LINC00689. Interestingly, the protein WDR60 is a dynein intermediary chain that is
essential for the assembly of cilia [157, 158]. Cilia sense external stimuli and direct these
signals influencing cell fate decisions such as growth or differentiation [159].
Interestingly, experimental ablation of cilia in the dermal cells causes an arrest of hair
follicle development [160], whereas cilia in the epidermal cells are involved in in
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epidermal stress responses, and normal keratinocyte differentiation [161]. Additionally,
cutaneous nerve fibers are present surrounding keratinocytes and cilia [162], which also
plays a role in maintaining interneuronal connectivity [163]. LINC00689 is a long noncoding RNAs (lncRNAs) produce transcripts over 200 nucleotides in length, which do
not translate in to proteins [132]. lncRNAs are found encapsulated in extracellular
vesicles of breastmilk [132] play a role in regulation of gene expression [133] and are
linked to actinic dermatosis [134] and psoriasis [135].
VII.

The CpG cg07208825 belongs to promoter region (TSS200) of ALMS1P, a pseudo gene
situated next to its parental gene ALMS1 (Centrosome and Basal Body Associated
Protein) on chromosome 2. Lower methylation of pseudogenes promoters are linked to
higher expression of parental gene expression [164, 165]. We find that the methylation of
cg07208825 (ALMS1P) is lower with longer duration of breastfeeding if the mother
smokes during pregnancy, which indicates a possibility of higher expression of the
parental gene ALMS1. Interestingly, ALMS1 plays a role assembly and function of cilia
[116] and interacts with actin cytoskeleton proteins important for cell-to-cell adhesion
[116].

Additional studies are warranted to further test the role of these genes in relation to
gestational smoking, breastfeeding duration and eczema in in other cohorts.
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Appendix
Supplementary Table A1: Association of exclusive breastfeeding duration with prevalence of
eczema (measured repeatedly at ages 1-or-2, 4, 10, and 18 years) stratified by maternal
smoking during pregnancy.
Maternal smoking during pregnancy
NO (n=3011)
YES (n=839)
Risk ratio
pRisk ratio
pParameter
Levels
(95% CI)
value
(95% CI)
value
Duration of exclusive
1.00 (0.99, 1.01)
0.75
0.97 (0.94, 0.99)
0.04
breastfeeding
0 weeks
3 weeks
0.91 (0.84, 0.99)
0.04
9 weeks
0.76 (0.58, 0.98)
0.04
15 weeks
0.63 (0.41, 0.97)
0.04
21 weeks
0.52 (0.29, 0.96)
0.04
FLG loss of function
1.5 (1.06, 2.06)
0.02
1.99 (1.02, 3.90)
0.04
variants
Time
Year 1/ 2
Ref.
Ref.
Ref.
Ref.
Year 4
0.76 (0.63, 0.92) 0.006
0.66 (0.4, 1.08)
0.10
Year 10
0.94 ( 0.78, 1.13)
0.51
0.98 (0.64, 1.48)
0.90
Year 18
0.74 (0.60, 0.92) 0.007 0.86 (0.54, 1.39)
0.55
Weeks of gestation
1.1 (1.0, 1.23)
0.09
1.12 (0.96, 1.33)
0.15
Maternal eczema
1.3 (0.97, 1.85)
0.07
1.17 (0.61, 2.24)
0.62
status
Paternal eczema
1.87 (1.32, 2.63) 0.0004 1.24 (0.54, 2.86)
0.61
status
Gender
Male
0.89 (0.70, 1.14)
0.36
1.06 (0.64, 1.76)
0.81
Socio economic status not added in the model since it did not have enough variability in the
smoking=’Yes’ group
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Supplementary Table A2: Assessing interaction of maternal smoking during pregnancy with
residuals of duration of exclusive breastfeeding on eczema at ages 1-or-2, 4, 10, and 18 adjusted
for covariates (n=3777).
Risk ratio
Parameter
Levels
(95% CI)
p-value
Maternal smoking during pregnancy
0.8 (0.60, 1.08)
0.15
Duration of exclusive breastfeeding
1.0(0.99, 1.01)
0.86
Maternal smoking during pregnancy ×
Residuals of duration of exclusive
breastfeeding#*
0 weeks
0.81 (0.60, 1.08)
0.15
3 weeks
0.74 (0.54, 1.0)
0.057
9 weeks
0.61 (0.40, 0.93)
0.02
15 weeks
0.51 (0.29, 0.88)
0.017
21 weeks
0.42 (0.21, 0.86)
0.018
FLG loss of function variants
1.57 (1.16, 2.13)
0.003
Time
Year 1/ 2
Ref.
Ref.
Year 4
0.74 (0.62, 0.88)
0.0012
Year 10
0.95 (0.80, 1.12)
0.54
Year 18
0.76 (0.63, 0.93 )
0.008
Weeks of gestation
1.10 (1.00, 1.21)
0.03
Maternal eczema status
1.31 (0.98, 1.76)
0.06
Paternal eczema status
1.74 (1.26, 2.41)
0.0008
Gender (Female is the reference)
Male
0.93 (0.75, 1.17)
0.57
Socio economic status
(High socioeconomic status is the reference)
Mid
1.09 (0.69, 1.72)
0.70
Low
1.06 (0.77, 1.46)
0.68
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Supplemental Table A3: Configural frequency analysis with complete data of eczema (no
missing at any time point) at age 1-or-2, 4, 10, and 18 (n=1006)
Observed Expected
Age Age Age Age
Classification into Types
Frequency Frequency p-value
1-2
4
10
18
and Antitypes*
(Fo)
(Fe)
701
573.202
0
Eczema free
+
42
74.709
4.19E-05 Antitype: Late onset
+
38
92.665
0
Antitype: at age 10 only
+
+
19
12.078
0.02254
+
22
71.09
0
Antitype: At age 4 only
+
+
5
9.266
0.079588
+
+
16
11.493
0.09057
+
+
+
3
1.498
0.109682
Antitype: At age 1&2
+
67
108.407
1.28E-05
only
+
+
7
14.129
0.028058
+
+
14
17.525
0.197789
+
+
+
7
2.284
0.000893 Type: Persistent eczema
+
+
16
13.445
0.241482
+
+
+
6
1.752
0.00066
Type: Persistent eczema
+
+
+
16
2.174
0
Type Persistent eczema
+
+
+
+
27
0.283
0
Type: Persistent eczema
*Antitypes: patterns that occur significantly less often than by chance
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Supplementary Table A4: Assessing interaction of maternal smoking during pregnancy and during
lactation, with duration of exclusive breastfeeding on eczema at ages 1-or-2, 4, 10, and 18 adjusted
for covariates (n=3780)
Risk ratio
Parameter
Levels
(95% CI)
p-value
Maternal smoking during pregnancy and/or lactation
0.99 (0.73, 1.33)
0.95
Duration of exclusive breastfeeding
1.0 (0.99, 1.01)
0.46
Maternal smoking during pregnancy and/or lactation
×
Duration of exclusive breastfeeding#*
0 weeks 0.99 (0.74, 1.33)
0.95
3 weeks
0.92 (0.71, 1.2)
0.55
9 weeks
0.8 (0.63, 1.02)
0.07
15 weeks 0.69 (0.52, 0.92)
0.01
21 weeks 0.60 (0.42, 0.87)
0.007
FLG loss of function variants
1.58 (1.17, 2.13)
0.0025
Time
Year 1/ 2
Ref.
Ref.
Year 4
0.74 (0.62, 89)
0.0012
Year 10 0.95 (0.80, 1.12)
0.54
Year 18 0.77 (0.63, 0.93)
0.007
Weeks of gestation
1.11 (1.01, 1.22)
0.02
Maternal eczema status
1.30 (0.98, 1.75)
0.07
Paternal eczema status
1.7 (1.23, 2.37)
0.0014
Gender (Female is the reference)
Male
0.94 (0.76, 1.17)
0.62
Socio economic status
(High socioeconomic status is the reference)
Mid
1.0 (0.68, 1.45)
0.99
Low
0.94 (0.59, 1.49)
0.99
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